10-Q · 2026-11-16
Guided Therapeutics Inc. reports quarterly results with a noted increase in short-term debt, reflecting ongoing financial adjustments in the electromedical industry.
| Name | GUIDED THERAPEUTICS INC |
|---|---|
| CIK | 0000924515 |
| Tickers | GTHP |
| Exchanges | OTC |
| Entity type | operating |
| Category | Non-accelerated filer<br>Smaller reporting company |
| SIC | 3845 Electromedical & Electrotherapeutic Apparatus |
| EIN | 582029543 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | 7702428723 |
| Website | — |
| Investor website | — |
| Owner org | 08 Industrial Applications and Services |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
Guided Therapeutics Inc. reports quarterly results with a noted increase in short-term debt, reflecting ongoing financial adjustments in the electromedical industry.
1162 filing rows loaded from submissions recent; extra archives: CIK0000924515-submissions-001.json (162 filings, 1997-02-27 to 2004-04-21).
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-16 | 10-Q | FORM 10-Q | 0001477932-26-007012 | 000-22179 | 261559161 | 34 | 8169584 | 1 | 1 | |
| 2026-10-27 | 4 | FORM 4 | 0001477932-26-006467 | 7759 | ||||||
| 2026-08-13 | 10-Q | FORM 10-Q | 0001477932-26-004958 | 000-22179 | 261271747 | 34 | 8445683 | 1 | 1 | |
| 2026-05-15 | 10-Q | FORM 10-Q | 0001477932-26-003195 | 000-22179 | 26985200 | 34 | 6863655 | 1 | 1 | |
| 2026-05-05 | 4 | FORM 4 | 0001477932-26-002770 | 30262 | ||||||
| 2026-04-07 | 4 | FORM 4 | 0001477932-26-002054 | 5707 | ||||||
| 2026-04-07 | 4 | FORM 4 | 0001477932-26-002052 | 14858 | ||||||
| 2026-04-07 | 4 | FORM 4 | 0001477932-26-002048 | 5720 | ||||||
| 2026-03-31 | 10-K | FORM 10-K | 0001477932-26-001723 | 000-22179 | 26815966 | 34 | 10285851 | 1 | 1 | |
| 2026-03-12 | 4 | FORM 4 | 0001477932-26-001320 | 33664 | ||||||
| 2026-03-10 | 8-K | FORM 8-K | 1.01,3.02,8.01,9.01 | 0001477932-26-001252 | 000-22179 | 26736614 | 34 | 136027 | 1 | 1 |
| 2026-03-04 | 4 | FORM 4 | 0001477932-26-001162 | 15786 | ||||||
| 2025-11-13 | 10-Q | FORM 10-Q | 0001477932-25-008196 | 000-22179 | 251479457 | 34 | 9550311 | 1 | 1 | |
| 2025-09-05 | 4 | FORM 4 | 0001477932-25-006531 | 12321 | ||||||
| 2025-09-05 | 4 | FORM 4 | 0001477932-25-006528 | 12194 | ||||||
| 2025-09-05 | 4 | FORM 4 | 0001477932-25-006522 | 13820 | ||||||
| 2025-09-05 | 4 | FORM 4 | 0001477932-25-006513 | 7370 | ||||||
| 2025-08-14 | 10-Q | FORM 10-Q | 0001477932-25-005887 | 000-22179 | 251217896 | 34 | 8427254 | 1 | 1 | |
| 2025-06-13 | 4 | FORM 4 | 0001477932-25-004576 | 5601 | ||||||
| 2025-06-12 | 4 | FORM 4 | 0001477932-25-004560 | 5585 | ||||||
| 2025-06-12 | 4 | FORM 4 | 0001477932-25-004559 | 5592 | ||||||
| 2025-05-23 | 4/A | FORM 4 A | 0001477932-25-004137 | 25162 | ||||||
| 2025-05-15 | 10-Q | FORM 10-Q | 0001477932-25-003835 | 000-22179 | 25954884 | 34 | 7836231 | 1 | 1 | |
| 2025-04-17 | 4 | FORM 4 | 0001477932-25-002818 | 24011 | ||||||
| 2025-04-08 | 4 | FORM 4 | 0001477932-25-002516 | 11270 | ||||||
| 2025-03-31 | 10-K | FORM 10-K | 0001477932-25-002200 | 000-22179 | 25792000 | 34 | 9500375 | 1 | 1 | |
| 2025-02-18 | 4 | FORM 4 | 0001477932-25-001072 | 4843 | ||||||
| 2024-12-23 | 8-K | FORM 8-K | 1.01,9.01 | 0001477932-24-008254 | 000-22179 | 241569225 | 34 | 441256 | 1 | 1 |
| 2024-12-20 | 4 | FORM 4 | 0001477932-24-008256 | 7265 | ||||||
| 2024-11-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001700205-24-000005 | 005-51261 | 241459513 | 34 | 81291 | |||
| 2024-11-14 | 10-Q | FORM 10-Q | 0001477932-24-007162 | 000-22179 | 241458790 | 34 | 8180394 | 1 | 1 | |
| 2024-10-25 | 4 | FORM 4 | 0001477932-24-006671 | 4843 | ||||||
| 2024-10-24 | 4 | FORM 4 | 0001477932-24-006656 | 7641 | ||||||
| 2024-10-02 | 4 | FORM 4 | 0001477932-24-006161 | 7266 | ||||||
| 2024-09-27 | 8-K | FORM 8-K | 1.01,9.01 | 0001477932-24-005960 | 000-22179 | 241329960 | 34 | 455718 | 1 | 1 |
| 2024-09-09 | 4 | FORM 4 | 0001477932-24-005604 | 7981 | ||||||
| 2024-09-06 | 4 | FORM 4 | 0001477932-24-005592 | 7990 | ||||||
| 2024-09-04 | 4 | FORM 4 | 0001477932-24-005518 | 5635 | ||||||
| 2024-09-03 | 4 | FORM 4 | 0001477932-24-005458 | 10235 | ||||||
| 2024-08-23 | 4 | FORM 4 | 0001477932-24-005227 | 4838 | ||||||
| 2024-08-22 | 4 | FORM 4 | 0001477932-24-005207 | 4846 | ||||||
| 2024-08-22 | 4 | FORM 4 | 0001477932-24-005206 | 4869 | ||||||
| 2024-08-14 | 10-Q | FORM 10-Q | 0001477932-24-004869 | 000-22179 | 241209691 | 34 | 13936342 | 1 | 1 | |
| 2024-08-01 | 4 | FORM 4 | 0001477932-24-004509 | 4843 | ||||||
| 2024-05-14 | 10-Q | FORM 10-Q | 0001477932-24-002788 | 000-22179 | 24940728 | 34 | 5947378 | 1 | 1 | |
| 2024-04-19 | 4 | FORM 4 | 0001477932-24-002247 | 6499 | ||||||
| 2024-04-05 | 4 | FORM 4 | 0001477932-24-001900 | 6526 | ||||||
| 2024-03-28 | 10-K | FORM 10-K | 0001477932-24-001549 | 000-22179 | 24800360 | 34 | 8333984 | 1 | 1 | |
| 2024-03-22 | 4 | FORM 4 | 0001477932-24-001435 | 7681 | ||||||
| 2024-02-22 | 4 | FORM 4 | 0001477932-24-000856 | 6499 | ||||||
| 2024-02-20 | SC 13G/A | rosalind_gthp_13ga_19feb.htm | 0001622627-24-000014 | 005-51261 | 24652191 | 34 | 89186 | |||
| 2024-02-14 | SC 13G/A | gthp_13gv2.htm | 0001700205-24-000003 | 005-51261 | 24635700 | 34 | 110924 | |||
| 2023-12-08 | 4 | FORM 4 | 0001477932-23-009031 | 13381 | ||||||
| 2023-11-13 | 10-Q | FORM 10-Q | 0001477932-23-008286 | 000-22179 | 231398155 | 34 | 7330982 | 1 | 1 | |
| 2023-09-20 | 4 | FORM 4 | 0001477932-23-006982 | 9561 | ||||||
| 2023-09-11 | 4 | FORM 4 | 0001477932-23-006793 | 4734 | ||||||
| 2023-09-07 | 4 | FORM 4 | 0001477932-23-006714 | 10791 | ||||||
| 2023-08-10 | 10-Q | FORM 10-Q | 0001477932-23-005869 | 000-22179 | 231158818 | 34 | 7257498 | 1 | 1 | |
| 2023-06-27 | 4 | FORM 4 | 0001477932-23-004807 | 17415 | ||||||
| 2023-06-27 | 4 | FORM 4 | 0001477932-23-004806 | 5538 | ||||||
| 2023-06-27 | 4 | FORM 4 | 0001477932-23-004805 | 5860 | ||||||
| 2023-06-27 | 4 | FORM 4 | 0001477932-23-004804 | 9187 | ||||||
| 2023-06-26 | 4 | FORM 4 | 0001477932-23-004759 | 4729 | ||||||
| 2023-06-26 | 4 | FORM 4 | 0001477932-23-004758 | 5474 | ||||||
| 2023-06-26 | 4 | FORM 4 | 0001477932-23-004757 | 9146 | ||||||
| 2023-06-20 | 3 | FORM 3 | 0001477932-23-004665 | 9444 | ||||||
| 2023-06-02 | 4 | FORM 4 | 0001477932-23-004226 | 5490 | ||||||
| 2023-06-02 | 4 | FORM 4 | 0001477932-23-004225 | 9138 | ||||||
| 2023-05-15 | 10-Q | FORM 10-Q | 0001477932-23-003493 | 000-22179 | 23920545 | 34 | 6566247 | 1 | 1 | |
| 2023-03-30 | 10-K | FORM 10-K | 0001477932-23-001899 | 000-22179 | 23776500 | 34 | 9268517 | 1 | 1 | |
| 2023-03-09 | 8-K | FORM 8-K | 5.02 | 0001477932-23-001383 | 000-22179 | 23720152 | 34 | 141234 | 1 | 1 |
| 2023-02-14 | SC 13G/A | gthpv5.htm | 0001700205-23-000002 | 005-51261 | 23625967 | 34 | 110861 | |||
| 2023-01-25 | EFFECT | xslEFFECTX01/primary_doc.xml | S-1,,2023-01-25 16:00:00 | 9999999995-23-000185 | 333-269229 | 23553807 | 33 | 1845 | ||
| 2023-01-23 | CORRESP | filename1.htm | 0001477932-23-000494 | 7609 | ||||||
| 2023-01-23 | UPLOAD | filename1.pdf | 0000000000-23-000693 | 40426 | ||||||
| 2023-01-13 | S-1 | FORM S-1 | 0001477932-23-000284 | 333-269229 | 23529408 | 33 | 15309774 | 1 | 1 | |
| 2022-12-02 | RW | RW | 0001477932-22-009056 | 333-259871 | 221442811 | NE | 6321 | |||
| 2022-11-14 | 10-Q | FORM 10-Q | 0001477932-22-008459 | 000-22179 | 221383418 | 34 | 7488893 | 1 | 1 | |
| 2022-10-24 | SC 13G | gthpv3.hm.htm | 0001700205-22-000003 | 005-51261 | 221326228 | 34 | 110905 | |||
| 2022-09-15 | 8-K | FORM 8-K | 1.01,3.02,8.01,9.01 | 0001477932-22-006945 | 000-22179 | 221246537 | 34 | 878444 | 1 | 1 |
| 2022-08-15 | 10-Q | FORM 10-Q | 0001477932-22-006064 | 000-22179 | 221164717 | 34 | 7570744 | 1 | 1 | |
| 2022-07-29 | 8-K | FORM 8-K | 3.03,5.03,9.01 | 0001477932-22-005479 | 000-22179 | 221117119 | 34 | 149016 | 1 | 1 |
| 2022-07-13 | S-1/A | FORM S-1/A | 0001477932-22-004988 | 333-259871 | 221080007 | 33 | 13936466 | 1 | 1 | |
| 2022-07-06 | SC 13G | SC 13G | 0001019056-22-000501 | 005-51261 | 221069206 | 34 | 133846 | |||
| 2022-06-30 | S-1/A | FORM S-1/A | 0001477932-22-004756 | 333-259871 | 221056200 | 33 | 14579048 | 1 | 1 | |
| 2022-05-16 | 10-Q | FORM 10-Q | 0001477932-22-003472 | 000-22179 | 22927619 | 34 | 6526674 | 1 | 1 | |
| 2022-03-30 | 10-K | FORM 10-K | 0001477932-22-001704 | 000-22179 | 22782712 | 34 | 11191327 | 1 | 1 | |
| 2022-02-17 | S-1/A | FORM S-1/A | 0001654954-22-001803 | 333-259871 | 22649430 | 33 | 17095480 | 1 | 1 | |
| 2022-01-07 | 8-K | FORM 8-K | 3.03,5.03,9.01 | 0001654954-22-000294 | 000-22179 | 22516383 | 34 | 153598 | 1 | 1 |
| 2021-11-15 | 10-Q | FORM 10Q | 0001654954-21-012222 | 000-22179 | 211410974 | 34 | 7668153 | 1 | 1 | |
| 2021-10-07 | S-1/A | FORM S-1/A | 0001568276-21-001658 | 333-259871 | 211310828 | 33 | 15767760 | 1 | 1 | |
| 2021-09-29 | S-1 | FORM S-1 | 0001568276-21-001601 | 333-259871 | 211288856 | 33 | 15749018 | 1 | 1 | |
| 2021-09-07 | 8-K | PRIMARY DOCUMENT | 1.01,8.01,9.01 | 0001654954-21-009799 | 000-22179 | 211238107 | 34 | 382624 | 1 | 1 |
| 2021-08-18 | 10-Q | PRIMARY DOCUMENT | 0001654954-21-009195 | 000-22179 | 211186421 | 34 | 8987579 | 1 | 1 | |
| 2021-08-18 | 10-Q/A | 10-Q/A | 0001654954-21-009188 | 000-22179 | 211186276 | 34 | 4158822 | 1 | ||
| 2021-08-16 | NT 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-21-000024 | 000-22179 | 211179856 | 34 | 29394 | |||
| 2021-07-27 | 8-K | GUIDED THERAPEUTICS, INC. | 5.07 | 0001121781-21-000023 | 000-22179 | 211118409 | 34 | 48374 | ||
| 2021-07-09 | 10-K/A | GUIDED THERAPEUTICS, INC. | 0001121781-21-000021 | 000-22179 | 211083468 | 34 | 182602 | |||
| 2021-07-07 | 8-K | GUIDED THERAPEUTICS, INC. | 8.01 | 0001121781-21-000019 | 000-22179 | 211077885 | 34 | 13798 | ||
| 2021-07-06 | DEF 14A | GUIDED THERAPEUTICS, INC. | 0001121781-21-000017 | 000-22179 | 211072224 | 34 | 585533 | |||
| 2021-06-22 | PRE 14A | GUIDED THERAPEUTICS, INC. | 0001121781-21-000015 | 000-22179 | 211032877 | 34 | 618564 | |||
| 2021-06-10 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,3.02,5.03,9.01 | 0001121781-21-000013 | 000-22179 | 211008693 | 34 | 136369 | ||
| 2021-05-21 | 10-Q | PRIMARY DOCUMENT | 0001654954-21-006101 | 000-22179 | 21945754 | 34 | 5048829 | 1 | ||
| 2021-05-17 | NT 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-21-000009 | 000-22179 | 21929562 | 34 | 28412 | |||
| 2021-04-07 | 10-K | ANNUAL REPORT | 0001654954-21-003915 | 000-22179 | 21810346 | 34 | 9052874 | 1 | ||
| 2021-03-31 | NT 10-K | GUIDED THERAPEUTICS, INC. | 0001121781-21-000005 | 000-22179 | 21793455 | 34 | 26863 | |||
| 2020-11-05 | 10-Q/A | GUIDED THERAPEUTICS, INC. | 0001121781-20-000080 | 000-22179 | 201289267 | 34 | 5261549 | 1 | ||
| 2020-11-05 | 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-20-000075 | 000-22179 | 201289156 | 34 | 1142550 | |||
| 2020-10-15 | EFFECT | xslEFFECTX01/primary_doc.xml | S-1,,2020-10-15 16:00:00 | 9999999995-20-002856 | 333-248712 | 201242696 | 33 | 1846 | ||
| 2020-10-13 | CORRESP | filename1.htm | 0001121781-20-000073 | 11930 | ||||||
| 2020-10-08 | S-1/A | S-1/A | 0001654954-20-010924 | 333-248712 | 201229938 | 33 | 10398002 | 1 | ||
| 2020-09-16 | 8-K | GUIDED THERAPEUTICS, INC. | 5.02 | 0001121781-20-000067 | 000-22179 | 201177880 | 34 | 17496 | ||
| 2020-09-14 | UPLOAD | filename1.pdf | 0000000000-20-008646 | 40457 | ||||||
| 2020-09-10 | S-1 | FORM S-1 | 0001654954-20-009997 | 333-248712 | 201169283 | 33 | 10248934 | 1 | ||
| 2020-08-20 | 10-Q | QUARTERLY REPORT | 0001654954-20-009366 | 000-22179 | 201117973 | 34 | 6398783 | 1 | ||
| 2020-08-17 | NT 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-20-000062 | 000-22179 | 201108210 | 34 | 28576 | |||
| 2020-07-07 | 10-Q | QUARTERLY REPORT | 0001654954-20-007405 | 000-22179 | 201015801 | 34 | 4656925 | 1 | ||
| 2020-06-29 | NT 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-20-000046 | 000-22179 | 20997345 | 34 | 28431 | |||
| 2020-05-18 | 8-K | GUIDED THERAPEUTICS, INC. | 8.01 | 0001121781-20-000041 | 000-22179 | 20888734 | 34 | 17545 | ||
| 2020-04-20 | 10-K | ANNUAL REPORT | 0001654954-20-004236 | 000-22179 | 20802309 | 34 | 13837839 | 1 | ||
| 2020-03-31 | 8-K | GUIDED THERAPEUTICS, INC. | 8.01 | 0001121781-20-000024 | 000-22179 | 20760312 | 34 | 17433 | ||
| 2020-03-09 | 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-20-000018 | 000-22179 | 20698004 | 34 | 4075831 | 1 | ||
| 2020-02-11 | 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-20-000011 | 000-22179 | 20594573 | 34 | 4031256 | 1 | ||
| 2019-08-15 | NT 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-19-000069 | 000-22179 | 191029932 | 34 | 28793 | |||
| 2019-07-11 | 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-19-000058 | 000-22179 | 19951481 | 34 | 3684529 | 1 | ||
| 2019-05-15 | NT 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-19-000036 | 000-22179 | 19827439 | 34 | 28473 | |||
| 2019-05-08 | 10-K | FORM 10-K | 0001654954-19-005469 | 000-22179 | 19807779 | 34 | 5547094 | 1 | ||
| 2019-04-03 | 8-K | GUIDED THERAPEUTICS, INC. | 5.02 | 0001121781-19-000020 | 000-22179 | 19728833 | 34 | 20984 | ||
| 2019-04-01 | NT 10-K | GUIDED THERAPEUTICS, INC. | 0001121781-19-000018 | 000-22179 | 19719336 | 34 | 27264 | |||
| 2018-11-15 | 8-K | GUIDED THERAPEUTICS, INC. | 5.03,9.01 | 0001121781-18-000070 | 000-22179 | 181185354 | 34 | 37291 | ||
| 2018-11-14 | 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-18-000063 | 000-22179 | 181181703 | 34 | 2945639 | 1 | ||
| 2018-10-25 | 8-K | GUIDED THERAPEUTICS, INC. | 5.07 | 0001121781-18-000056 | 000-22179 | 181137854 | 34 | 40582 | ||
| 2018-10-11 | DEF 14A | GUIDED THERAPEUTICS, INC. | 0001121781-18-000046 | 000-22179 | 181117444 | 34 | 489550 | |||
| 2018-09-28 | PRE 14A | GUIDED THERAPEUTICS, INC. | 0001121781-18-000042 | 000-22179 | 181093009 | 34 | 470548 | |||
| 2018-09-17 | DEF 14A | GUIDED THERAPEUTICS, INC. | 0001121781-18-000035 | 000-22179 | 181073364 | 34 | 455867 | |||
| 2018-09-06 | 8-K | CURRENT REPORT | 1.01,3.02,5.03,9.01 | 0001654954-18-009920 | 000-22179 | 181057227 | 34 | 180511 | ||
| 2018-09-05 | PRE 14A | GUIDED THERAPEUTICS, INC. | 0001121781-18-000033 | 000-22179 | 181054393 | 34 | 455642 | |||
| 2018-08-14 | 10-Q | QUARTERLY REPORT | 0001654954-18-009034 | 000-22179 | 181015361 | 34 | 3058150 | 1 | ||
| 2018-07-10 | EFFECT | xslEFFECTX01/primary_doc.xml | S-1,,2018-07-10 16:00:00 | 9999999995-18-001746 | 333-225613 | 18947962 | 33 | 1827 | ||
| 2018-07-09 | CORRESP | filename1.htm | 0001121781-18-000028 | 6806 | ||||||
| 2018-07-02 | UPLOAD | filename1.pdf | 0000000000-18-020357 | 38786 | ||||||
| 2018-06-14 | S-1 | REGISTRATION STATEMENT | 0001654954-18-006646 | 333-225613 | 18898691 | 33 | 6108693 | 1 | ||
| 2018-05-25 | SC 13D | SC 13D | 0001193125-18-174721 | 005-51261 | 18860537 | 34 | 32758 | |||
| 2018-05-25 | 3 | FORM 3 SUBMISSION | 0000899243-18-014024 | 8210 | ||||||
| 2018-05-21 | 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-18-000024 | 000-22179 | 18848766 | 34 | 2692253 | 1 | ||
| 2018-05-15 | NT 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-18-000019 | 000-22179 | 18833967 | 34 | 26527 | |||
| 2018-04-20 | 10-K/A | PRIMARY DOCUMENT | 0001654954-18-004170 | 000-22179 | 18765866 | 34 | 3970941 | 1 | ||
| 2018-04-17 | 10-K | ANNUAL REPORT | 0001654954-18-004021 | 000-22179 | 18758657 | 34 | 3963277 | 1 | ||
| 2018-04-02 | NT 10-K | GUIDED THERAPEUTICS, INC. | 0001121781-18-000010 | 000-22179 | 18727721 | 34 | 26328 | |||
| 2017-11-20 | 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-17-000077 | 000-22179 | 171214809 | 34 | 2527839 | 1 | ||
| 2017-11-15 | NT 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-17-000076 | 000-22179 | 171204422 | 34 | 18329 | |||
| 2017-11-13 | 8-K/A | GUIDED THERAPEUTICS, INC. | 1.01,2.03,3.02,9.01 | 0001121781-17-000071 | 000-22179 | 171192530 | 34 | 190082 | ||
| 2017-10-25 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,2.03,3.02,9.01 | 0001121781-17-000059 | 000-22179 | 171153137 | 34 | 177571 | ||
| 2017-09-25 | RW | GUIDED THERAPEUTICS, INC. | 0001121781-17-000056 | 333-212384 | 171099514 | NE | 5650 | |||
| 2017-08-24 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,2.03,3.02,9.01 | 0001121781-17-000051 | 000-22179 | 171049832 | 34 | 187635 | ||
| 2017-08-18 | 10-Q | QUARTERLY REPORT | 0001654954-17-007742 | 000-22179 | 171040517 | 34 | 2739960 | 1 | ||
| 2017-08-17 | 8-K/A | FORM 8K/A | 1.01,9.01 | 0001654954-17-007712 | 000-22179 | 171038424 | 34 | 97341 | ||
| 2017-08-15 | NT 10-Q | NT 10-Q | 0001654954-17-007608 | 000-22179 | 171033134 | 34 | 29174 | |||
| 2017-08-14 | 8-K | CURRENT REPORT | 1.01,9.01 | 0001654954-17-007533 | 000-22179 | 171030013 | 34 | 93883 | ||
| 2017-06-26 | S-1/A | PRIMARY DOCUMENT | 0001654954-17-005874 | 333-212384 | 17930075 | 33 | 6326195 | 1 | ||
| 2017-06-07 | S-1/A | FORM S-1/A AMENDMENT NO. 4 | 0001654954-17-005425 | 333-212384 | 17897313 | 33 | 6903365 | 1 | ||
| 2017-05-24 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,2.03,3.02,9.01 | 0001121781-17-000036 | 000-22179 | 17864826 | 34 | 1196928 | ||
| 2017-05-22 | 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-17-000030 | 000-22179 | 17859192 | 34 | 2496861 | 1 | ||
| 2017-05-15 | NT 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-17-000027 | 000-22179 | 17843795 | 34 | 17735 | |||
| 2017-03-31 | S-1/A | S-1/A | 0001654954-17-002848 | 333-212384 | 17728480 | 33 | 4757153 | 1 | ||
| 2017-03-30 | 424B3 | GUIDEN THERAPEUTICS, INC. | 0001121781-17-000019 | 333-210387 | 17726602 | 33 | 26722 | |||
| 2017-03-30 | 8-K | GUIDEN THERAPEUTICS, INC. | 1.01 | 0001121781-17-000018 | 000-22179 | 17726550 | 34 | 37739 | ||
| 2017-03-24 | 424B3 | PROSPECTUS SUPPLEMENT NO. 15 | 0001654954-17-002459 | 333-210387 | 17713662 | 33 | 119725 | |||
| 2017-03-24 | 8-K/A | CURRENT REPORT AMENDMENT NO. 1 | 1.01,3.02,5.05,9.01 | 0001654954-17-002454 | 000-22179 | 17713288 | 34 | 113776 | ||
| 2017-03-22 | 10-K | ANNUAL REPORT | 0001654954-17-002258 | 000-22179 | 17706338 | 34 | 4040560 | 1 | ||
| 2017-03-09 | SC 13G | formsc13g.htm | 0001493152-17-002284 | 005-51261 | 17677943 | 34 | 90580 | |||
| 2017-02-17 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-17-000013 | 333-210387 | 17619474 | 33 | 34149 | |||
| 2017-02-17 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,2.03,3.02,9.01 | 0001121781-17-000012 | 000-22179 | 17619473 | 34 | 384579 | ||
| 2017-01-26 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-17-000008 | 333-210387 | 17548656 | 33 | 31900 | |||
| 2017-01-26 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,3.02,5.05,9.01 | 0001121781-17-000006 | 000-22179 | 17548645 | 34 | 178917 | ||
| 2017-01-12 | S-1/A | GUIDED THERAPEUTICS, INC. | 0001121781-17-000004 | 333-212384 | 17525480 | 33 | 5459858 | 1 | ||
| 2016-12-30 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000605 | 333-210387 | 162077754 | 33 | 33622 | |||
| 2016-12-30 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,2.03,3.02,9.01 | 0001121781-16-000604 | 000-22179 | 162077736 | 34 | 370596 | ||
| 2016-12-09 | S-1/A | GUIDED THERAPEUTICS, INC. | 0001121781-16-000599 | 333-212384 | 162042665 | 33 | 5693719 | 1 | ||
| 2016-12-08 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000594 | 333-210387 | 162041574 | 33 | 22302 | |||
| 2016-12-08 | 8-K | GUIDED THERAPEUTICS, INC. | 5.02 | 0001121781-16-000593 | 000-22179 | 162041512 | 34 | 17987 | ||
| 2016-12-08 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000592 | 333-210387 | 162040017 | 33 | 27094 | |||
| 2016-12-07 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,9.01 | 0001121781-16-000591 | 000-22179 | 162039970 | 34 | 221673 | ||
| 2016-12-05 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000586 | 333-210387 | 162034563 | 33 | 372178 | |||
| 2016-12-05 | 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-16-000585 | 000-22179 | 162034540 | 34 | 2436863 | 1 | ||
| 2016-11-18 | 3 | OWNERSHIP DOCUMENT | 0001121781-16-000576 | 11268 | ||||||
| 2016-11-17 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000574 | 333-210387 | 162005028 | 33 | 23200 | |||
| 2016-11-17 | 8-K | GUIDED THERAPEUTICS, INC. | 5.02 | 0001121781-16-000573 | 000-22179 | 162005004 | 34 | 18927 | ||
| 2016-11-15 | NT 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-16-000569 | 000-22179 | 161999847 | 34 | 17733 | |||
| 2016-11-04 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000559 | 333-210387 | 161975398 | 33 | 27554 | |||
| 2016-11-04 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,8.01,9.01 | 0001121781-16-000558 | 000-22179 | 161975334 | 34 | 57608 | ||
| 2016-09-23 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000545 | 333-210387 | 161899594 | 33 | 40966 | |||
| 2016-09-23 | 8-K | GUIDED THERAPEUTICS, INC. | 5.07 | 0001121781-16-000544 | 000-22179 | 161899573 | 34 | 37676 | ||
| 2016-09-09 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000540 | 333-210387 | 161877988 | 33 | 27460 | |||
| 2016-09-09 | 8-K/A | GUIDED THERAPEUTICS, INC. | 1.01,2.03,9.01 | 0001121781-16-000539 | 000-22179 | 161877971 | 34 | 36897 | ||
| 2016-09-08 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000537 | 333-210387 | 161876451 | 33 | 26606 | |||
| 2016-09-08 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,2.03,9.01 | 0001121781-16-000536 | 000-22179 | 161876426 | 34 | 36012 | ||
| 2016-08-26 | DEFA14A | GUIDED THERAPEUTICS, INC. | 0001121781-16-000530 | 000-22179 | 161854145 | 34 | 23499 | |||
| 2016-08-25 | DEF 14A | GUIDED THERAPEUTICS, INC. | 0001121781-16-000528 | 000-22179 | 161850973 | 34 | 163898 | |||
| 2016-08-19 | UPLOAD | filename1.pdf | 0000000000-16-089297 | 36081 | ||||||
| 2016-08-18 | PRER14A | GUIDED THERAPEUTICS, INC. | 0001121781-16-000520 | 000-22179 | 161840442 | 34 | 165473 | |||
| 2016-08-18 | CORRESP | filename1.htm | 0001121781-16-000519 | 5743 | ||||||
| 2016-08-18 | 8-K | GUIDED THERAPEUTICS, INC. | 2.02,7.01,9.01 | 0001121781-16-000517 | 000-22179 | 161840239 | 34 | 86780 | ||
| 2016-08-17 | 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-16-000515 | 000-22179 | 161838711 | 34 | 2359363 | 1 | ||
| 2016-08-16 | NT 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-16-000513 | 000-22179 | 161835136 | 34 | 17461 | |||
| 2016-08-12 | PRE 14A | GUIDED THERAPEUTICS, INC. | 0001121781-16-000509 | 000-22179 | 161827930 | 34 | 164696 | |||
| 2016-08-12 | CORRESP | filename1.htm | 0001121781-16-000508 | 27554 | ||||||
| 2016-08-03 | PRE 14A | GUIDED THERAPEUTICS, INC. | 0001121781-16-000506 | 000-22179 | 161804670 | 34 | 165439 | |||
| 2016-08-03 | CORRESP | filename1.htm | 0001121781-16-000505 | 25983 | ||||||
| 2016-07-27 | UPLOAD | filename1.pdf | 0000000000-16-085965 | 160538 | ||||||
| 2016-07-19 | CORRESP | filename1.htm | 0001654954-16-000863 | 25888 | ||||||
| 2016-07-19 | PRER14A | PRELIMINARY PROXY STATEMENT | 0001654954-16-000862 | 000-22179 | 161773906 | 34 | 256395 | |||
| 2016-07-19 | UPLOAD | filename1.pdf | 0000000000-16-084876 | 160975 | ||||||
| 2016-07-07 | PRE 14A | GUIDED THERAPEUTICS, INC. | 0001121781-16-000501 | 000-22179 | 161756590 | 34 | 150950 | |||
| 2016-07-07 | CORRESP | filename1.htm | 0001121781-16-000500 | 73524 | ||||||
| 2016-07-01 | S-1 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000497 | 333-212384 | 161747020 | 33 | 5302893 | 1 | ||
| 2016-06-29 | UPLOAD | filename1.pdf | 0000000000-16-082605 | 160083 | ||||||
| 2016-06-15 | CORRESP | filename1.htm | 0001121781-16-000491 | 6393 | ||||||
| 2016-06-15 | PRE 14A | GUIDED THERAPEUTICS, INC. | 0001121781-16-000490 | 000-22179 | 161715355 | 34 | 150188 | |||
| 2016-06-14 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000488 | 333-210387 | 161712087 | 33 | 28296 | |||
| 2016-06-14 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,3.02,9.01 | 0001121781-16-000486 | 000-22179 | 161712055 | 34 | 189517 | ||
| 2016-06-08 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000482 | 333-210387 | 161703702 | 33 | 30057 | |||
| 2016-06-08 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,2.03,3.02,9.01 | 0001121781-16-000480 | 000-22179 | 161703674 | 34 | 107322 | 1 | |
| 2016-05-19 | 8-K | GUIDED THERAPEUTICS, INC. | 2.02,7.01,9.01 | 0001121781-16-000474 | 000-22179 | 161662103 | 34 | 68258 | 1 | |
| 2016-05-19 | 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-16-000472 | 000-22179 | 161662092 | 34 | 2386820 | 1 | ||
| 2016-05-17 | NT 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-16-000468 | 000-22179 | 161656200 | 34 | 17184 | |||
| 2016-05-11 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000459 | 333-210387 | 161640805 | 33 | 20712 | |||
| 2016-05-11 | 8-K | GUIDED THERAPEUTICS, INC. | 5.02 | 0001121781-16-000458 | 000-22179 | 161640746 | 34 | 16258 | ||
| 2016-05-04 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000454 | 333-210387 | 161616740 | 33 | 34875 | |||
| 2016-05-03 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,3.02,5.03,9.01 | 0001121781-16-000452 | 000-22179 | 161616604 | 34 | 157180 | ||
| 2016-04-18 | SC 13G | SCHEDULE 13G | 0001078782-16-002658 | 005-51261 | 161576429 | 34 | 49625 | |||
| 2016-04-07 | EFFECT | xslEFFECTX01/primary_doc.xml | S-1,,2016-04-07 17:00:00 | 9999999995-16-004165 | 333-210387 | 161561226 | 33 | 1828 | ||
| 2016-04-07 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000436 | 333-210387 | 161560844 | 33 | 801750 | |||
| 2016-04-05 | CORRESP | filename1.htm | 0001121781-16-000434 | 17423 | ||||||
| 2016-03-31 | 8-K | GUIDED THERAPEUTICS, INC. | 7.01,9.01 | 0001121781-16-000429 | 000-22179 | 161543762 | 34 | 53491 | 1 | |
| 2016-03-24 | S-1 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000424 | 333-210387 | 161527093 | 33 | 3540195 | 1 | ||
| 2016-03-15 | 8-K | GUIDED THERAPEUTICS, INC. | 2.02,7.01,9.01 | 0001121781-16-000422 | 000-22179 | 161507048 | 34 | 151417 | 1 | |
| 2016-03-15 | 10-K | GUIDED THERAPEUTICS, INC. | 0001121781-16-000420 | 000-22179 | 161506800 | 34 | 3559759 | 1 | ||
| 2016-03-07 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000416 | 333-207201 | 161489236 | 33 | 25834 | |||
| 2016-03-07 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000415 | 333-205676 | 161489224 | 33 | 25720 | |||
| 2016-03-07 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000414 | 333-203589 | 161489217 | 33 | 25707 | |||
| 2016-03-07 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000413 | 333-198733 | 161489210 | 33 | 26071 | |||
| 2016-03-07 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,9.01 | 0001121781-16-000411 | 000-22179 | 161488465 | 34 | 46776 | ||
| 2016-02-23 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000405 | 333-207201 | 161449281 | 33 | 27314 | |||
| 2016-02-23 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000404 | 333-205676 | 161449269 | 33 | 27215 | |||
| 2016-02-23 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000403 | 333-203589 | 161449251 | 33 | 27400 | |||
| 2016-02-23 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000402 | 333-198733 | 161449236 | 33 | 27993 | |||
| 2016-02-23 | 8-K | GUIDED THERAPEUTICS, INC. | 8.01,9.01 | 0001121781-16-000400 | 000-22179 | 161448231 | 34 | 42230 | ||
| 2016-02-16 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000394 | 333-207201 | 161421644 | 33 | 47647 | |||
| 2016-02-16 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000393 | 333-205676 | 161421638 | 33 | 47665 | |||
| 2016-02-16 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000392 | 333-203589 | 161421629 | 33 | 47915 | |||
| 2016-02-16 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-16-000391 | 333-198733 | 161421619 | 33 | 48086 | |||
| 2016-02-16 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,2.03,2.04,3.02,5.02,9.01 | 0001121781-16-000390 | 000-22179 | 161421423 | 34 | 671348 | ||
| 2015-12-18 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000354 | 333-207201 | 151294715 | 33 | 20066 | |||
| 2015-12-18 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000353 | 333-205676 | 151294709 | 33 | 20063 | |||
| 2015-12-18 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000352 | 333-203589 | 151294707 | 33 | 20057 | |||
| 2015-12-18 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000351 | 333-198733 | 151294706 | 33 | 20190 | |||
| 2015-12-17 | 10-Q/A | GUIDED THERAPEUTICS, INC. | 0001121781-15-000350 | 000-22179 | 151294581 | 34 | 24264 | |||
| 2015-11-13 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000325 | 333-207201 | 151230097 | 33 | 321597 | |||
| 2015-11-13 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000324 | 333-205676 | 151230087 | 33 | 321492 | |||
| 2015-11-13 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000323 | 333-203589 | 151230078 | 33 | 321595 | |||
| 2015-11-13 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000322 | 333-198733 | 151230055 | 33 | 321526 | |||
| 2015-11-13 | 8-K | GUIDED THERAPEUTICS, INC. | 2.02,7.01,9.01 | 0001121781-15-000320 | 000-22179 | 151228946 | 34 | 120616 | ||
| 2015-11-12 | 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-15-000315 | 000-22179 | 151225065 | 34 | 2072368 | 1 | ||
| 2015-11-12 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000312 | 333-207201 | 151223894 | 33 | 48737 | |||
| 2015-11-12 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000311 | 333-205676 | 151223884 | 33 | 48761 | |||
| 2015-11-12 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000310 | 333-203589 | 151223879 | 33 | 48654 | |||
| 2015-11-12 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000309 | 333-198733 | 151223870 | 33 | 48946 | |||
| 2015-11-12 | 8-K | GUIDED THERAPEUTICS, INC. | 5.07 | 0001121781-15-000307 | 000-22179 | 151223151 | 34 | 45408 | ||
| 2015-11-10 | 8-K | GUIDED THERAPEUTICS, INC. | 8.01,9.01 | 0001121781-15-000303 | 000-22179 | 151218330 | 34 | 44011 | ||
| 2015-10-16 | EFFECT | xslEFFECTX01/primary_doc.xml | S-1,,2015-10-16 17:00:00 | 9999999995-15-002776 | 333-207201 | 151162935 | 33 | 1828 | ||
| 2015-10-16 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000293 | 333-207201 | 151162667 | 33 | 1016117 | |||
| 2015-10-15 | UPLOAD | filename1.pdf | 0000000000-15-049910 | 188969 | ||||||
| 2015-10-15 | CORRESP | filename1.htm | 0001121781-15-000291 | 9093 | ||||||
| 2015-10-14 | DEF 14A | GUIDED THERAPEUTICS, INC. | 0001121781-15-000287 | 000-22179 | 151158224 | 34 | 134629 | |||
| 2015-10-07 | SC 13G/A | dbm13ga.txt | 0001310611-15-000004 | 005-51261 | 151148559 | 34 | 10358 | |||
| 2015-10-05 | SC 13G | dbm13gq315.txt | 0001310611-15-000003 | 005-51261 | 151141633 | 34 | 10864 | |||
| 2015-10-02 | PRE 14A | GUIDED THERAPEUTICS, INC. | 0001121781-15-000279 | 000-22179 | 151140987 | 34 | 134598 | |||
| 2015-09-30 | S-1 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000275 | 333-207201 | 151133573 | 33 | 4572581 | 1 | ||
| 2015-09-15 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000263 | 333-203589 | 151107711 | 33 | 31734 | |||
| 2015-09-15 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000262 | 333-205676 | 151107702 | 33 | 31769 | |||
| 2015-09-15 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000260 | 333-198733 | 151107695 | 33 | 32191 | |||
| 2015-09-15 | 8-K | GUIDED THERAPEUTICS, INC. | 5.07 | 0001121781-15-000258 | 000-22179 | 151107323 | 34 | 27529 | ||
| 2015-09-03 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000252 | 333-205676 | 151091910 | 33 | 32472 | |||
| 2015-09-03 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000250 | 333-203589 | 151091894 | 33 | 32582 | |||
| 2015-09-03 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000248 | 333-198733 | 151091886 | 33 | 32673 | |||
| 2015-09-03 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,3.02,3.03,5.03,9.01 | 0001121781-15-000246 | 000-22179 | 151091758 | 34 | 106173 | ||
| 2015-08-20 | 8-K | GUIDED THERAPEUTICS, INC. | 7.01,9.01 | 0001121781-15-000244 | 000-22179 | 151065880 | 34 | 45048 | ||
| 2015-08-20 | 8-K | GUIDED THERAPEUTICS, INC. | 7.01,9.01 | 0001121781-15-000242 | 000-22179 | 151065732 | 34 | 43298 | ||
| 2015-08-13 | 8-K | GUIDED THERAPEUTICS, INC. | 2.02,7.01,9.01 | 0001121781-15-000232 | 000-22179 | 151050953 | 34 | 126606 | ||
| 2015-08-13 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000230 | 333-203589 | 151049030 | 33 | 354112 | |||
| 2015-08-13 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000228 | 333-205676 | 151049000 | 33 | 354423 | |||
| 2015-08-13 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000226 | 333-198733 | 151048991 | 33 | 354574 | |||
| 2015-08-13 | 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-15-000224 | 000-22179 | 151048792 | 34 | 2131423 | 1 | ||
| 2015-07-31 | DEF 14A | GUIDED THERAPEUTICS, INC. | 0001121781-15-000215 | 000-22179 | 151019299 | 34 | 125046 | |||
| 2015-07-30 | EFFECT | xslEFFECTX01/primary_doc.xml | S-1,,2015-07-30 17:00:00 | 9999999995-15-002118 | 333-205676 | 151017752 | 33 | 1828 | ||
| 2015-07-30 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000213 | 333-205676 | 151017204 | 33 | 884854 | |||
| 2015-07-29 | 8-K | GUIDED THERAPEUTICS, INC. | 7.01,9.01 | 0001121781-15-000211 | 000-22179 | 151010563 | 34 | 42502 | ||
| 2015-07-28 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000209 | 333-205676 | 151008417 | 33 | 884224 | |||
| 2015-07-28 | CORRESP | filename1.htm | 0001121781-15-000207 | 6790 | ||||||
| 2015-07-24 | UPLOAD | filename1.pdf | 0000000000-15-038435 | 153865 | ||||||
| 2015-07-20 | PRE 14A | GUIDED THERAPEUTICS, INC. | 0001121781-15-000205 | 000-22179 | 15995296 | 34 | 125042 | |||
| 2015-07-17 | 4 | OWNERSHIP DOCUMENT | 0001121781-15-000201 | 9157 | ||||||
| 2015-07-17 | 4 | OWNERSHIP DOCUMENT | 0001121781-15-000199 | 15796 | ||||||
| 2015-07-17 | 4 | OWNERSHIP DOCUMENT | 0001121781-15-000197 | 23827 | ||||||
| 2015-07-15 | D | xslFormDX01/primary_doc.xml | 06b | 0000924515-15-000001 | 021-243795 | 15989144 | 33 | 12510 | ||
| 2015-07-15 | S-1 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000195 | 333-205676 | 15989057 | 33 | 4089731 | 1 | ||
| 2015-07-13 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000193 | 333-203589 | 15985833 | 33 | 25298 | |||
| 2015-07-13 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000191 | 333-198733 | 15985817 | 33 | 25354 | |||
| 2015-07-13 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,3.02,9.01 | 0001121781-15-000189 | 000-22179 | 15985784 | 34 | 59513 | ||
| 2015-06-30 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000179 | 333-203589 | 15960797 | 33 | 49559 | |||
| 2015-06-30 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000177 | 333-198733 | 15960791 | 33 | 50004 | |||
| 2015-06-30 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,2.03,3.02,9.01 | 0001121781-15-000175 | 000-22179 | 15960036 | 34 | 1040832 | ||
| 2015-06-19 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000166 | 333-203589 | 15941852 | 33 | 26941 | |||
| 2015-06-19 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000165 | 333-198733 | 15941850 | 33 | 27273 | |||
| 2015-06-19 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,3.02,5.03,9.01 | 0001121781-15-000164 | 000-22179 | 15941848 | 34 | 27880 | ||
| 2015-06-08 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000159 | 333-203589 | 15916936 | 33 | 57553 | |||
| 2015-06-08 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000157 | 333-198733 | 15916919 | 33 | 57655 | |||
| 2015-06-05 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,3.02,9.01 | 0001121781-15-000155 | 000-22179 | 15916806 | 34 | 63834 | ||
| 2015-05-29 | 8-K | GUIDED THERAPEUTICS, INC. | 5.07 | 0001121781-15-000150 | 000-22179 | 15898418 | 34 | 32396 | ||
| 2015-05-20 | 8-K | GUIDED THERAPEUTICS, INC. | 7.01,9.01 | 0001121781-15-000146 | 000-22179 | 15879736 | 34 | 51543 | ||
| 2015-05-18 | SC 13G | MUSKET 13G | 0001310611-15-000002 | 005-51261 | 15872884 | 34 | 10563 | |||
| 2015-05-14 | 8-K | GUIDED THERAPEUTICS, INC. | 2.02,7.01,9.01 | 0001121781-15-000128 | 000-22179 | 15863266 | 34 | 104717 | ||
| 2015-05-13 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000124 | 333-203589 | 15859191 | 33 | 256158 | |||
| 2015-05-13 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000123 | 333-198733 | 15859177 | 33 | 256372 | |||
| 2015-05-13 | 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-15-000121 | 000-22179 | 15858384 | 34 | 2339920 | 1 | ||
| 2015-05-07 | EFFECT | xslEFFECTX01/primary_doc.xml | S-1,,2015-05-07 17:00:00 | 9999999995-15-001265 | 333-203589 | 15843851 | 33 | 1827 | ||
| 2015-05-07 | EFFECT | xslEFFECTX01/primary_doc.xml | POS AM,0001121781-15-000087,2015-05-07 | 9999999995-15-001254 | 333-198733 | 15843844 | 33 | 1840 | ||
| 2015-05-07 | 424B4 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000115 | 333-203589 | 15842876 | 33 | 927327 | |||
| 2015-05-07 | 424B4 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000114 | 333-198733 | 15842861 | 33 | 667585 | |||
| 2015-05-07 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,3.02,9.01 | 0001121781-15-000111 | 000-22179 | 15841718 | 34 | 75088 | ||
| 2015-04-27 | DEF 14A | GUIDED THERAPEUTICS, INC. | 0001121781-15-000089 | 000-22179 | 15794552 | 34 | 170829 | |||
| 2015-04-23 | POS AM | GUIDED THERAPEUTICS, INC. | 0001121781-15-000087 | 333-198733 | 15789066 | 33 | 4035327 | 1 | ||
| 2015-04-23 | S-1 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000085 | 333-203589 | 15788995 | 33 | 4323137 | 1 | ||
| 2015-04-16 | 8-K | GUIDED THERAPEUTICS, INC. | 7.01,9.01 | 0001121781-15-000075 | 000-22179 | 15774274 | 34 | 37061 | ||
| 2015-04-14 | PRE 14A | GUIDED THERAPEUTICS, INC. | 0001121781-15-000073 | 000-22179 | 15769303 | 34 | 171078 | |||
| 2015-04-10 | 4 | OWNERSHIP DOCUMENT | 0001121781-15-000070 | 4717 | ||||||
| 2015-04-10 | 4 | OWNERSHIP DOCUMENT | 0001121781-15-000068 | 4711 | ||||||
| 2015-03-30 | 8-K | GUIDED THERAPEUTICS, INC. | 2.02,7.01,9.01 | 0001121781-15-000058 | 000-22179 | 15734560 | 34 | 112811 | ||
| 2015-03-25 | 10-K | GUIDED THERAPEUTICS, INC. | 0001121781-15-000054 | 000-22179 | 15724820 | 34 | 3965016 | 1 | ||
| 2015-03-19 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000052 | 333-198733 | 15713048 | 33 | 26622 | |||
| 2015-03-19 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-15-000051 | 333-195603 | 15713032 | 33 | 25896 | |||
| 2015-03-19 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,3.02,9.01 | 0001121781-15-000049 | 000-22179 | 15712974 | 34 | 76845 | ||
| 2015-01-16 | 4 | OWNERSHIP DOCUMENT | 0001121781-15-000006 | 4717 | ||||||
| 2015-01-16 | 4 | OWNERSHIP DOCUMENT | 0001121781-15-000004 | 4719 | ||||||
| 2014-12-19 | UPLOAD | filename1.pdf | 0000000000-14-066045 | 34194 | ||||||
| 2014-12-19 | CORRESP | filename1.htm | 0001121781-14-000383 | 9350 | ||||||
| 2014-12-17 | UPLOAD | filename1.pdf | 0000000000-14-065068 | 157074 | ||||||
| 2014-12-09 | 4 | OWNERSHIP DOCUMENT | 0001121781-14-000374 | 6944 | ||||||
| 2014-12-09 | 4 | OWNERSHIP DOCUMENT | 0001121781-14-000372 | 6981 | ||||||
| 2014-12-04 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-14-000368 | 333-195603 | 141264676 | 33 | 29479 | |||
| 2014-12-04 | 8-K/A | GUIDED THERAPEUTICS, INC. | 1.01,3.02,8.01,9.01 | 0001121781-14-000366 | 000-22179 | 141264644 | 34 | 492376 | ||
| 2014-12-03 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,3.02,8.01,9.01 | 0001121781-14-000364 | 000-22179 | 141263957 | 34 | 411138 | ||
| 2014-11-26 | 424B4 | GUIDED THERAPEUTICS, INC. | 0001121781-14-000359 | 333-198733 | 141253195 | 33 | 883249 | |||
| 2014-11-20 | 8-K | GUIDED THERAPEUTICS, INC. | 7.01,9.01 | 0001121781-14-000355 | 000-22179 | 141237834 | 34 | 39300 | ||
| 2014-11-19 | EFFECT | xslEFFECTX01/primary_doc.xml | S-1,,2014-11-19 16:00:00 | 9999999995-14-003456 | 333-198733 | 141237364 | 33 | 1828 | ||
| 2014-11-19 | S-1/A | GUIDED THERAPEUTICS, INC. | 0001121781-14-000345 | 333-198733 | 141233570 | 33 | 5264104 | 1 | ||
| 2014-11-14 | 8-K | GUIDED THERAPEUTICS, INC. | 2.02,7.01,9.01 | 0001121781-14-000334 | 000-22179 | 141223458 | 34 | 110225 | ||
| 2014-11-12 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-14-000324 | 333-195603 | 141213393 | 33 | 261754 | |||
| 2014-11-12 | 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-14-000322 | 000-22179 | 141212890 | 34 | 2039456 | 1 | ||
| 2014-11-10 | S-1/A | GUIDED THERAPEUTICS, INC. | 0001121781-14-000318 | 333-198733 | 141209789 | 33 | 1177726 | |||
| 2014-10-21 | 4 | OWNERSHIP DOCUMENT | 0001121781-14-000312 | 4719 | ||||||
| 2014-10-21 | 4 | OWNERSHIP DOCUMENT | 0001121781-14-000310 | 4637 | ||||||
| 2014-09-15 | S-1 | GUIDED THERAPEUTICS, INC. | 0001121781-14-000293 | 333-198733 | 141101735 | 33 | 5276882 | 1 | ||
| 2014-09-10 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-14-000290 | 333-195603 | 141096096 | 33 | 24420 | |||
| 2014-09-10 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,9.01 | 0001121781-14-000289 | 000-22179 | 141096086 | 34 | 169792 | ||
| 2014-09-08 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-14-000285 | 333-195603 | 141091492 | 33 | 25571 | |||
| 2014-09-08 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,3.02,9.01 | 0001121781-14-000284 | 000-22179 | 141091473 | 34 | 164362 | ||
| 2014-08-20 | 4 | OWNERSHIP DOCUMENT | 0001121781-14-000273 | 4677 | ||||||
| 2014-08-20 | 4 | OWNERSHIP DOCUMENT | 0001121781-14-000271 | 4682 | ||||||
| 2014-08-20 | 4 | OWNERSHIP DOCUMENT | 0001121781-14-000269 | 4638 | ||||||
| 2014-08-20 | 4 | OWNERSHIP DOCUMENT | 0001121781-14-000267 | 4640 | ||||||
| 2014-08-18 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-14-000251 | 333-195603 | 141049036 | 33 | 259038 | |||
| 2014-08-14 | 8-K | GUIDED THERAPEUTICS, INC. | 2.02,7.01,9.01 | 0001121781-14-000244 | 000-22179 | 141043699 | 34 | 131903 | ||
| 2014-08-13 | 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-14-000235 | 000-22179 | 141037915 | 34 | 2093076 | 1 | ||
| 2014-07-28 | 8-K | GUIDED THERAPEUTICS, INC. | 9.01 | 0001121781-14-000223 | 000-22179 | 14996410 | 34 | 38628 | ||
| 2014-07-17 | 8-K | GUIDED THERAPEUTICS, INC. | 7.01,9.01 | 0001121781-14-000219 | 000-22179 | 14979764 | 34 | 37921 | ||
| 2014-07-08 | 4 | OWNERSHIP DOCUMENT | 0001121781-14-000217 | 9327 | ||||||
| 2014-07-08 | 8-K | GUIDED THERAPEUTICS, INC. | 7.01,9.01 | 0001121781-14-000215 | 000-22179 | 14964875 | 34 | 37854 | ||
| 2014-06-26 | 4 | OWNERSHIP DOCUMENT | 0001121781-14-000205 | 4610 | ||||||
| 2014-06-26 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-14-000203 | 333-195603 | 14941715 | 33 | 46310 | |||
| 2014-06-20 | 8-K | GUIDED THERAPEUTICS, INC. | 5.07 | 0001121781-14-000201 | 000-22179 | 14933492 | 34 | 41897 | ||
| 2014-06-20 | 4 | OWNERSHIP DOCUMENT | 0001121781-14-000199 | 8539 | ||||||
| 2014-06-18 | 4 | OWNERSHIP DOCUMENT | 0001121781-14-000193 | 4539 | ||||||
| 2014-06-03 | 4 | OWNERSHIP DOCUMENT | 0001121781-14-000179 | 4766 | ||||||
| 2014-06-02 | 4 | OWNERSHIP DOCUMENT | 0001121781-14-000173 | 4764 | ||||||
| 2014-05-28 | 8-K | GUIDED THERAPEUTICS, INC. | 7.01,9.01 | 0001121781-14-000166 | 000-22179 | 14870810 | 34 | 76488 | ||
| 2014-05-23 | 8-K | GUIDED THERAPEUTICS, INC. | 7.01,9.01 | 0001121781-14-000164 | 000-22179 | 14867499 | 34 | 33309 | ||
| 2014-05-19 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-14-000150 | 333-195603 | 14854061 | 33 | 222204 | |||
| 2014-05-19 | 8-K | GUIDED THERAPEUTICS, INC. | 2.02,7.01,9.01 | 0001121781-14-000148 | 000-22179 | 14854051 | 34 | 86919 | ||
| 2014-05-15 | 10-Q | GUIDED THERAPEUTICS, INC. | 0001121781-14-000134 | 000-22179 | 14847835 | 34 | 1857586 | 1 | ||
| 2014-05-13 | DEF 14A | GUIDED THERAPEUTICS, INC. | 0001121781-14-000120 | 000-22179 | 14838046 | 34 | 153448 | |||
| 2014-05-13 | D | xslFormDX01/primary_doc.xml | 06b | 0000924515-14-000001 | 021-217241 | 14835977 | 33 | 12187 | ||
| 2014-05-12 | EFFECT | xslEFFECTX01/primary_doc.xml | S-1,,2014-05-12 17:00:00 | 9999999995-14-001435 | 333-195603 | 14835262 | 33 | 1827 | ||
| 2014-05-12 | 424B3 | GUIDED THERAPEUTICS, INC. | 0001121781-14-000118 | 333-195603 | 14834515 | 33 | 799420 | |||
| 2014-05-09 | S-1/A | GUIDED THERAPEUTICS, INC. | 0001121781-14-000114 | 333-195603 | 14829349 | 33 | 3962589 | 1 | ||
| 2014-05-02 | PRE 14A | GUIDED THERAPEUTICS, INC. | 0001121781-14-000110 | 000-22179 | 14809768 | 34 | 152675 | |||
| 2014-04-30 | S-1 | GUIDED THERAPEUTICS, INC. | 0001121781-14-000108 | 333-195603 | 14800429 | 33 | 3970459 | 1 | ||
| 2014-04-24 | 8-K | GUIDED THERAPEUTICS, INC. | 1.01,2.03,3.02,9.01 | 0001121781-14-000096 | 000-22179 | 14780227 | 34 | 426279 | ||
| 2014-04-15 | 8-K | GUIDED THERAPEUTICS, INC. | 7.01,9.01 | 0001121781-14-000087 | 000-22179 | 14764425 | 34 | 37780 |
One latest value per concept from companyfacts (467 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 98.19M | 2026-11-11 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| dei | EntityPublicFloat | Entity Public Float | USD | 10.52M | 2025-06-30 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 | |
| us-gaap | AccountsAndNotesReceivableNet | Accounts and Financing Receivable, after Allowance for Credit Loss | USD | 2,000 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-13 | 0001477932-25-008196 | |
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 2.36M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | AccountsPayableRelatedPartiesCurrent | Accounts Payable, Related Parties, Current | USD | 29,000 | 2023-03-31 | 2023 | Q1 | 10-Q | 2023-05-15 | 0001477932-23-003493 | |
| us-gaap | AccountsReceivableGrossCurrent | Accounts Receivable, before Allowance for Credit Loss, Current | USD | 2,669 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-31 | 0001477932-25-002200 | |
| us-gaap | AccountsReceivableNet | Accounts Receivable, after Allowance for Credit Loss | USD | 29,000 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0001477932-22-008459 | |
| us-gaap | AccountsReceivableNetCurrent | Accounts Receivable, after Allowance for Credit Loss, Current | USD | 3,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | AccretionExpense | Accretion Expense | USD | 83,366 | 2023-07-01 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-13 | 0001477932-23-008286 |
| us-gaap | AccruedBonusesCurrentAndNoncurrent | Accrued Bonuses | USD | 570,000 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 | |
| us-gaap | AccruedLiabilities | Accrued Liabilities (Deprecated 2009-01-31) | USD | 773,000 | 2011-06-30 | 2011 | Q2 | 10-Q | 2011-11-14 | 0001121781-11-000340 | |
| us-gaap | AccruedLiabilitiesCurrent | Accrued Liabilities, Current | USD | 1.37M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | AccruedLiabilitiesCurrentAndNoncurrent | Accrued Liabilities | USD | 1.13M | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 | |
| us-gaap | AccruedProfessionalFeesCurrent | Accrued Professional Fees, Current | USD | 40,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | AccruedProfessionalFeesCurrentAndNoncurrent | Accrued Professional Fees | USD | 37,000 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 | |
| us-gaap | AccruedRentCurrent | Accrued Rent, Current | USD | 0 | 2017-12-31 | 2017 | FY | 10-K/A | 2018-04-20 | 0001654954-18-004170 | |
| us-gaap | AccruedVacationCurrent | Accrued Vacation, Current | USD | 42,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | AccruedVacationCurrentAndNoncurrent | Accrued Vacation | USD | 40,000 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 | |
| us-gaap | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | USD | 1.58M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | AdditionalLiabilityLongDurationInsuranceRemeasurementGainLoss | AdditionalLiabilityLongDurationInsuranceRemeasurementGainLoss | USD | 62,000 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | AdditionalPaidInCapital | Additional Paid in Capital | USD | 149.08M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | AdditionsToNoncurrentAssets | Segment Reporting Information, Expenditures for Additions to Long-Lived Assets (Deprecated 2013-01-31) | USD | -107,000 | 2013-01-01 | 2013-12-31 | 2013 | FY | 10-K | 2014-03-26 | 0001121781-14-000055 |
| us-gaap | AdjustmentForAmortization | Amortization | USD | 0 | 2022-01-01 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0001477932-22-008459 |
| us-gaap | AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities | Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities | USD | 682,000 | 2021-01-01 | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-18 | 0001654954-21-009195 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature | USD | 6,000 | 2024-01-01 | 2024-06-30 | 2024 | Q2 | 10-Q | 2024-08-14 | 0001477932-24-004869 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalOther | Adjustments to Additional Paid in Capital, Other | USD | 151,000 | 2021-01-01 | 2021-03-31 | 2021 | Q1 | 10-Q/A | 2021-08-18 | 0001654954-21-009188 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions | APIC, Share-based Payment Arrangement, Recognition and Exercise | USD | 68,000 | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | USD | 101,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition | USD | 227,000 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-30 | 0001477932-22-001704 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalWarrantIssued | Adjustments to Additional Paid in Capital, Warrant Issued | USD | 18,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | AllocatedShareBasedCompensationExpense | Share-based Payment Arrangement, Expense | USD | 377,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 |
| us-gaap | AllowanceForDoubtfulAccountsReceivable | Accounts Receivable, Allowance for Credit Loss | USD | 4,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease | Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) | USD | 19,000 | 2015-01-01 | 2015-12-31 | 2015 | FY | 10-K | 2016-03-15 | 0001121781-16-000420 |
| us-gaap | AllowanceForLoanAndLeaseLossRecoveryOfBadDebts | Allowance for Loan and Lease Loss, Recovery of Bad Debts | USD | 0 | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-15 | 0001654954-21-012222 |
| us-gaap | AmortizationOfFinancingCosts | Amortization of Debt Issuance Costs | USD | 0 | 2011-01-01 | 2011-12-31 | 2011 | FY | 10-K | 2012-03-28 | 0001121781-12-000081 |
| us-gaap | AmortizationOfFinancingCostsAndDiscounts | Amortization of Debt Issuance Costs and Discounts | USD | 140,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | AmortizationOfIntangibleAssets | Amortization of Intangible Assets | USD | 543,000 | 2015-01-01 | 2015-06-30 | 2015 | Q2 | 10-Q | 2015-08-13 | 0001121781-15-000224 |
| us-gaap | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 28,244 | 2022-01-01 | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-15 | 0001477932-22-006064 |
| us-gaap | Assets | Assets | USD | 1.38M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 734,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | AssetsNet | Net Assets | USD | -8.00M | 2020-12-31 | 2020 | FY | 10-K | 2021-04-07 | 0001654954-21-003915 | |
| us-gaap | AssetsNoncurrent | Assets, Noncurrent | USD | 642,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment | Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment | USD | 18,000 | 2019-12-31 | 2019 | FY | 10-K | 2020-04-20 | 0001654954-20-004236 | |
| us-gaap | BusinessAcquisitionProFormaEarningsPerShareBasic | Business Acquisition, Pro Forma Earnings Per Share, Basic | USD/shares | -0.01 | 2025-01-01 | 2025-03-31 | 2025 | Q1 | 10-Q | 2025-05-15 | 0001477932-25-003835 |
| us-gaap | CapitalizedComputerSoftwareAdditions | Capitalized Computer Software, Additions | USD | 640,000 | 1998-01-01 | 2012-12-31 | 2012 | FY | 10-K | 2013-03-27 | 0001121781-13-000037 |
| us-gaap | CapitalizedComputerSoftwareNet | Capitalized Computer Software, Net | USD | 0 | 2011-12-31 | 2011 | FY | 10-K | 2012-03-28 | 0001121781-12-000081 | |
| us-gaap | CapitalUnitsAuthorized | Capital Units, Authorized | shares | 145.00M | 2012-12-31 | 2012 | FY | 10-K | 2013-03-27 | 0001121781-13-000037 | |
| us-gaap | CapitalUnitsOutstanding | Capital Units, Outstanding | shares | 62.19M | 2012-09-30 | 2012 | Q3 | 10-Q | 2012-11-13 | 0001121781-12-000323 | |
| us-gaap | Cash | Cash | USD | 899,000 | 2019-12-31 | 2019 | FY | 10-K | 2020-04-20 | 0001654954-20-004236 | |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 731,000 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-13 | 0001477932-23-008286 | |
| us-gaap | CashAndCashEquivalentsPeriodIncreaseDecrease | Cash and Cash Equivalents, Period Increase (Decrease) | USD | 359,000 | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-15 | 0001654954-21-012222 |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | 111,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | USD | 48,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | USD | -273,000 | 2025-01-01 | 2025-03-31 | 2025 | Q1 | 10-Q | 2025-05-15 | 0001477932-25-003835 |
| us-gaap | CashFDICInsuredAmount | Cash, FDIC Insured Amount | USD | 2.06M | 2022-12-31 | 2022 | FY | 10-K | 2023-03-30 | 0001477932-23-001899 | |
| us-gaap | ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 | Class of Warrant or Right, Exercise Price of Warrants or Rights | USD/shares | 0.4 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight | Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares | 7.18M | 2020-01-16 | 2021 | FY | 10-K | 2022-03-30 | 0001477932-22-001704 | |
| us-gaap | ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights | Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 35.94M | 2020-01-16 | 2021 | FY | 10-K | 2022-03-30 | 0001477932-22-001704 | |
| us-gaap | ClassOfWarrantOrRightOutstanding | Class of Warrant or Right, Outstanding | shares | 39.79M | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 | |
| us-gaap | CommitmentsAndContingencies | Commitments and Contingencies | USD | 0 | 2019-12-31 | 2019 | Q3 | 10-Q | 2020-03-09 | 0001121781-20-000018 | |
| us-gaap | CommonStockCapitalSharesReservedForFutureIssuance | Common Stock, Capital Shares Reserved for Future Issuance | shares | 2.50M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | CommonStockDividendsShares | Common Stock Dividends, Shares | shares | 3.45M | 2023-01-01 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-13 | 0001477932-23-008286 |
| us-gaap | CommonStockOtherSharesOutstanding | Common Stock, Other Shares, Outstanding | shares | 6.57M | 2012-09-30 | 2012 | Q3 | 10-Q | 2012-11-13 | 0001121781-12-000323 | |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0.001 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 500,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 98,188 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 98,188 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | CommonStockSharesSubscriptions | Common Stock, Value, Subscriptions | USD | 351,000 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-30 | 0001477932-22-001704 | |
| us-gaap | CommonStocksIncludingAdditionalPaidInCapital | Common Stocks, Including Additional Paid in Capital | USD | 103,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 3.48M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | CommonUnitOutstanding | Common Unit, Outstanding | shares | 52.04M | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-13 | 0001477932-23-008286 | |
| us-gaap | ContractWithCustomerAssetReclassifiedToReceivable | Contract with Customer, Asset, Reclassified to Receivable | USD | 120,000 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | ContractWithCustomerReceivableAllowanceForCreditLoss | Contract with Customer, Receivable, Allowance for Credit Loss | USD | 586 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-31 | 0001477932-25-002200 | |
| us-gaap | ConversionOfStockAmountConverted1 | Conversion of Stock, Amount Converted | USD | 319,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | ConversionOfStockAmountIssued1 | Conversion of Stock, Amount Issued | USD | 75,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 |
| us-gaap | ConversionOfStockSharesConverted1 | Conversion of Stock, Shares Converted | shares | 414,082 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 |
| us-gaap | ConversionOfStockSharesIssued1 | Conversion of Stock, Shares Issued | shares | 100,000 | 2024-01-01 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-14 | 0001477932-24-007162 |
| us-gaap | ConvertibleDebt | Convertible Debt | USD | 2.40M | 2019-12-17 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 | |
| us-gaap | ConvertibleDebtCurrent | Convertible Debt, Current | USD | 73,000 | 2019-12-31 | 2019 | FY | 10-K | 2020-04-20 | 0001654954-20-004236 | |
| us-gaap | ConvertibleDebtFairValueDisclosures | Convertible Debt, Fair Value Disclosures | USD | 388,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | ConvertibleDebtNoncurrent | Convertible Debt, Noncurrent | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 | |
| us-gaap | ConvertibleLongTermNotesPayable | Convertible Notes Payable, Noncurrent | USD | 1.11M | 2024-03-31 | 2024 | Q1 | 10-Q | 2024-05-14 | 0001477932-24-002788 | |
| us-gaap | ConvertibleNotesPayable | Convertible Notes Payable | USD | 0 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0001477932-22-008459 | |
| us-gaap | ConvertibleNotesPayableCurrent | Convertible Notes Payable, Current | USD | 311,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue | Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value | USD | 105,000 | 2019-12-31 | 2019 | FY | 10-K | 2020-04-20 | 0001654954-20-004236 | |
| us-gaap | CostOfGoodsAndServicesSold | Cost of Goods and Services Sold | USD | 2,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | CostOfGoodsSold | Cost of Goods Sold (Deprecated 2018-01-31) | USD | 3,000 | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-21 | 0001121781-18-000024 |
| us-gaap | CostOfRevenue | Cost of Revenue | USD | 42,000 | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-15 | 0001654954-21-012222 |
| us-gaap | CostsAndExpenses | Costs and Expenses | USD | 1.71M | 2012-01-01 | 2012-03-31 | 2012 | Q1 | 10-Q | 2012-05-14 | 0001121781-12-000160 |
| us-gaap | CumulativeEarningsDeficit | Cumulative Earnings (Deficit) | USD | -158.00M | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 | |
| us-gaap | CurrentIncomeTaxExpenseBenefit | Current Income Tax Expense (Benefit) | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 |
| us-gaap | DebtConversionConvertedInstrumentAmount1 | Debt Conversion, Converted Instrument, Amount | USD | 33,000 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-04-20 | 0001654954-20-004236 |
| us-gaap | DebtConversionConvertedInstrumentSharesIssued1 | Debt Conversion, Converted Instrument, Shares Issued | shares | 2.25M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 |
| us-gaap | DebtDefaultShorttermDebtAmount | Debt Default, Short-term Debt, Amount | USD | 1.13M | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-14 | 0001477932-24-007162 | |
| us-gaap | DebtInstrumentConvertibleBeneficialConversionFeature | Debt Instrument, Convertible, Beneficial Conversion Feature | USD | 217,000 | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 |
| us-gaap | DebtInstrumentDecreaseForgiveness | Debt Instrument, Decrease, Forgiveness | USD | 191,051 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-30 | 0001477932-23-001899 |
| us-gaap | DebtInstrumentFaceAmount | Debt Instrument, Face Amount | USD | 2.50M | 2021-12-31 | 2021 | FY | 10-K | 2022-03-30 | 0001477932-22-001704 | |
| us-gaap | DebtInstrumentFairValue | Debt Instrument, Fair Value Disclosure | USD | 2.74M | 2021-12-31 | 2021 | FY | 10-K | 2022-03-30 | 0001477932-22-001704 | |
| us-gaap | DebtInstrumentIncreaseAccruedInterest | Debt Instrument, Increase, Accrued Interest | USD | 116,000 | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 |
| us-gaap | DebtInstrumentInterestRateDuringPeriod | Debt Instrument, Interest Rate During Period | pure | 0.06 | 2024-04-01 | 2024-04-15 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | DebtInstrumentInterestRateEffectivePercentage | Debt Instrument, Interest Rate, Effective Percentage | pure | 0.046 | 2015-09-30 | 2015 | Q3 | 10-Q | 2015-11-12 | 0001121781-15-000315 | |
| us-gaap | DebtInstrumentInterestRateEffectivePercentageRateRangeMaximum | Debt Instrument, Interest Rate, Effective Percentage Rate Range, Maximum (Deprecated 2016-01-31) | pure | 0.18 | 2012-01-01 | 2012-09-30 | 2012 | Q3 | 10-Q | 2012-11-13 | 0001121781-12-000323 |
| us-gaap | DebtInstrumentInterestRateEffectivePercentageRateRangeMinimum | Debt Instrument, Interest Rate, Effective Percentage Rate Range, Minimum (Deprecated 2016-01-31) | pure | 0.15 | 2012-01-01 | 2012-09-30 | 2012 | Q3 | 10-Q | 2012-11-13 | 0001121781-12-000323 |
| us-gaap | DebtInstrumentInterestRateStatedPercentage | Debt Instrument, Interest Rate, Stated Percentage | pure | 0.24 | 2025-03-31 | 2025 | Q1 | 10-Q | 2025-05-15 | 0001477932-25-003835 | |
| us-gaap | DebtInstrumentPeriodicPaymentPrincipal | Debt Instrument, Periodic Payment, Principal | USD | 161,184 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-30 | 0001477932-23-001899 |
| us-gaap | DebtInstrumentUnamortizedDiscount | Debt Instrument, Unamortized Discount | USD | 7,000 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-14 | 0001477932-24-007162 | |
| us-gaap | DebtInstrumentUnamortizedDiscountCurrent | Debt Instrument, Unamortized Discount, Current | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 | |
| us-gaap | DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | USD | 0 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-30 | 0001477932-23-001899 | |
| us-gaap | DebtInstrumentUnamortizedPremium | Debt Instrument, Unamortized Premium | USD | 9,000 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 | |
| us-gaap | DeferredCompensationLiabilityClassifiedNoncurrent | Deferred Compensation Liability, Classified, Noncurrent | USD | 82,000 | 2024-04-15 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | DeferredCompensationLiabilityCurrent | Deferred Compensation Liability, Current | USD | 388,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | DeferredFinanceCostsNet | Debt Issuance Costs, Net | USD | 0 | 2015-09-30 | 2015 | Q3 | 10-Q | 2015-11-12 | 0001121781-15-000315 | |
| us-gaap | DeferredIncomeTaxExpenseBenefit | Deferred Income Tax Expense (Benefit) | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 |
| us-gaap | DeferredRentCredit | Deferred Rent Credit | USD | 0 | 2017-09-30 | 2017 | Q3 | 10-Q | 2017-11-20 | 0001121781-17-000077 | |
| us-gaap | DeferredRevenue | Deferred Revenue | USD | 189,000 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 | |
| us-gaap | DeferredRevenueCurrent | Deferred Revenue, Current | USD | 269,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | DeferredTaxAssetsGross | Deferred Tax Assets, Gross | USD | 17.40M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 | |
| us-gaap | DeferredTaxAssetsGrossCurrent | Deferred Tax Assets, Gross, Current | USD | 795,000 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-22 | 0001654954-17-002258 | |
| us-gaap | DeferredTaxAssetsNet | Deferred Tax Assets, Net of Valuation Allowance | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwards | Deferred Tax Assets, Operating Loss Carryforwards | USD | 15.61M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration | Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration | USD | 3.00M | 2025-12-31 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | DeferredTaxAssetsOther | Deferred Tax Assets, Other | USD | 211,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 | |
| us-gaap | DeferredTaxAssetsOtherLossCarryforwards | Deferred Tax Assets, Other Loss Carryforwards | USD | 48.60M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits | USD | 440,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other | USD | 861,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | USD | 237,000 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-28 | 0001477932-24-001549 | |
| us-gaap | DeferredTaxAssetsValuationAllowance | Deferred Tax Assets, Valuation Allowance | USD | 17.40M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 | |
| us-gaap | DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets | Deferred Tax Liabilities, Intangible Assets | USD | 0 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-22 | 0001654954-17-002258 | |
| us-gaap | DepositAssets | Deposit Assets | USD | 493,000 | 2020-09-30 | 2020 | Q3 | 10-Q/A | 2020-11-05 | 0001121781-20-000080 | |
| us-gaap | DepositLiabilitiesAccruedInterest | Deposit Liabilities, Accrued Interest | USD | 13,760 | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-15 | 0001477932-22-006064 | |
| us-gaap | Deposits | Deposits | USD | 99,000 | 2019-06-30 | 2019 | Q2 | 10-Q | 2020-02-11 | 0001121781-20-000011 | |
| us-gaap | Depreciation | Depreciation | USD | 7,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | DepreciationAndAmortization | Depreciation, Depletion and Amortization, Nonproduction | USD | 483,000 | 2014-01-01 | 2014-12-31 | 2014 | FY | 10-K | 2015-03-25 | 0001121781-15-000054 |
| us-gaap | DepreciationDepletionAndAmortization | Depreciation, Depletion and Amortization | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-04-07 | 0001654954-21-003915 |
| us-gaap | DepreciationNonproduction | Depreciation, Nonproduction | USD | 6.95M | 2023-01-01 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-13 | 0001477932-23-008286 |
| us-gaap | DerivativeFairValueOfDerivativeLiability | Derivative Liability, Fair Value, Gross Liability | USD | 20,000 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-14 | 0001477932-24-007162 | |
| us-gaap | DerivativeGainLossOnDerivativeNet | Derivative, Gain (Loss) on Derivative, Net | USD | 39,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | DerivativeLiabilities | Derivative Liability | USD | 37,000 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 | |
| us-gaap | DerivativeLiabilitiesCurrent | Derivative Liability, Current | USD | 43,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | DerivativeLiabilitiesNoncurrent | Derivative Liability, Noncurrent | USD | 0 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-28 | 0001477932-24-001549 | |
| us-gaap | DerivativeLiabilityFairValueOfCollateral | Derivative Liability, Fair Value of Collateral | USD | 326,016 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-30 | 0001477932-23-001899 | |
| us-gaap | DerivativeLiabilityNotionalAmount | Derivative Liability, Notional Amount | USD | 298,884 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0001477932-22-008459 | |
| us-gaap | DirectFinancingLeaseRevenue | Direct Financing Lease, Revenue | USD | 4.00M | 2022-06-01 | 2022-06-22 | 2022 | Q3 | 10-Q | 2022-11-14 | 0001477932-22-008459 |
| us-gaap | DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment | Disposal Group, Including Discontinued Operation, Property, Plant and Equipment | USD | 647.00M | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-15 | 0001654954-21-012222 | |
| us-gaap | DividendsPayableCurrent | Dividends Payable, Current | USD | 120,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | DividendsPreferredStock | Dividends, Preferred Stock | USD | 3,000 | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 |
| us-gaap | DividendsPreferredStockStock | Dividends, Preferred Stock, Stock | USD | 36,000 | 2025-01-01 | 2025-03-31 | 2025 | Q1 | 10-Q | 2025-05-15 | 0001477932-25-003835 |
| us-gaap | DueToRelatedPartiesCurrent | Due to Related Parties, Current | USD | 497,000 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0001477932-22-008459 | |
| us-gaap | DueToRelatedPartiesCurrentAndNoncurrent | Due to Related Parties | USD | 354,000 | 2017-12-31 | 2017 | FY | 10-K/A | 2018-04-20 | 0001654954-18-004170 | |
| us-gaap | DueToRelatedPartiesNoncurrent | Due to Related Parties, Noncurrent | USD | 83,000 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-30 | 0001477932-23-001899 | |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -0.02 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | EarningsPerShareBasicAndDiluted | Earnings Per Share, Basic and Diluted | USD/shares | -1.29 | 2017-01-01 | 2017-12-31 | 2017 | FY | 10-K/A | 2018-04-20 | 0001654954-18-004170 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -0.02 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | EffectiveIncomeTaxRateContinuingOperations | Effective Income Tax Rate Reconciliation, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 |
| us-gaap | EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | pure | 0.21 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | pure | -0.25 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpense | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 |
| us-gaap | EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | pure | 0.04 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 |
| us-gaap | EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity | Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity | USD | 1.10M | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-30 | 0001477932-22-001704 |
| us-gaap | EmployeeRelatedLiabilitiesCurrent | Employee-related Liabilities, Current | USD | 1.12M | 2019-12-31 | 2019 | FY | 10-K | 2020-04-20 | 0001654954-20-004236 | |
| us-gaap | EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | USD | 170,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | EmployeeStockOwnershipPlanESOPDeferredShares | Employee Stock Ownership Plan (ESOP), Deferred Shares | USD | 284,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 | |
| us-gaap | EntityWideRevenueMajorCustomerPercentage | Entity-Wide Revenue, Major Customer, Percentage (Deprecated 2013-01-31) | pure | 0.65 | 2013-01-01 | 2013-12-31 | 2013 | FY | 10-K | 2014-03-26 | 0001121781-14-000055 |
| us-gaap | EquityFairValueDisclosure | Equity, Fair Value Disclosure | USD | -2.23M | 2020-12-31 | 2020 | FY | 10-K | 2021-04-07 | 0001654954-21-003915 | |
| us-gaap | EquityMethodInvestmentOwnershipPercentage | Equity Method Investment, Ownership Percentage | pure | 0.1 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-28 | 0001477932-24-001549 | |
| us-gaap | ExcessStockSharesIssued | Excess Stock, Shares Issued | shares | 875,000 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-28 | 0001477932-24-001549 | |
| us-gaap | ExplorationExpense | Exploration Expense | USD | 270,000 | 2025-01-01 | 2025-12-31 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | ExtinguishmentOfDebtAmount | Extinguishment of Debt, Amount | USD | 0 | 2022-01-01 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0001477932-22-008459 |
| us-gaap | FairValueAdjustmentOfWarrants | Fair Value Adjustment of Warrants | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-30 | 0001477932-23-001899 |
| us-gaap | FinanceLeaseRightOfUseAssetAmortization | Finance Lease, Right-of-Use Asset, Amortization | USD | 50,000 | 2022-01-01 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0001477932-22-008459 |
| us-gaap | GainLossOnDispositionOfAssets | Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property | USD | 177,685 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-28 | 0001477932-24-001549 |
| us-gaap | GainLossOnRepurchaseOfDebtInstrument | Gain (Loss) on Repurchase of Debt Instrument | USD | 160,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | GainLossOnSaleOfDerivatives | Gain (Loss) on Sale of Derivatives | USD | 0 | 2024-01-01 | 2024-03-31 | 2024 | Q1 | 10-Q | 2024-05-14 | 0001477932-24-002788 |
| us-gaap | GainLossOnSaleOfPropertyPlantEquipment | Gain (Loss) on Disposition of Property Plant Equipment | USD | 8,000 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | GainsLossesOnExtinguishmentOfDebt | Gain (Loss) on Extinguishment of Debt | USD | 0 | 2026-01-01 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-13 | 0001477932-26-004958 |
| us-gaap | GainsLossesOnRestructuringOfDebt | Gains (Losses) on Restructuring of Debt | USD | 60,000 | 2012-01-01 | 2012-12-31 | 2012 | FY | 10-K | 2013-03-27 | 0001121781-13-000037 |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 1.26M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | GrossProfit | Gross Profit | USD | 90,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | IncomeLossFromContinuingOperations | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | USD | -6.64M | 2011-01-01 | 2011-12-31 | 2011 | FY | 10-K | 2012-03-28 | 0001121781-12-000081 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic | Income (Loss) from Continuing Operations before Income Taxes, Domestic | USD | -3.56M | 2013-01-01 | 2013-06-30 | 2013 | Q2 | 10-Q | 2013-08-14 | 0001121781-13-000294 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | USD | -1.82M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments | Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest | USD | -3.49M | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-28 | 0001477932-24-001549 |
| us-gaap | IncomeLossFromContinuingOperationsPerBasicAndDilutedShare | Income (Loss) from Continuing Operations, Per Basic and Diluted Share | USD/shares | -0.14 | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-15 | 0001654954-21-012222 |
| us-gaap | IncomeLossFromContinuingOperationsPerBasicShare | Income (Loss) from Continuing Operations, Per Basic Share | USD/shares | -0.01 | 2025-01-01 | 2025-03-31 | 2025 | Q1 | 10-Q | 2025-05-15 | 0001477932-25-003835 |
| us-gaap | IncomeTaxExpenseBenefit | Income Tax Expense (Benefit) | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | USD | 164,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 |
| us-gaap | IncomeTaxReconciliationChangeInEnactedTaxRate | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount | USD | 0 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-04-20 | 0001654954-20-004236 |
| us-gaap | IncomeTaxReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount | USD | -164,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 |
| us-gaap | IncomeTaxReconciliationOtherReconcilingItems | Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount | USD | 0 | 2021-01-01 | 2021-03-31 | 2021 | Q1 | 10-Q/A | 2021-08-18 | 0001654954-21-009188 |
| us-gaap | IncreaseDecreaseInAccountsPayable | Increase (Decrease) in Accounts Payable | USD | -55,000 | 2021-01-01 | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-18 | 0001654954-21-009195 |
| us-gaap | IncreaseDecreaseInAccountsPayableAndAccruedLiabilities | Increase (Decrease) in Accounts Payable and Accrued Liabilities | USD | 235,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | IncreaseDecreaseInAccountsReceivable | Increase (Decrease) in Accounts Receivable | USD | -1,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | IncreaseDecreaseInAccruedLiabilities | Increase (Decrease) in Accrued Liabilities | USD | 70,000 | 2021-01-01 | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-18 | 0001654954-21-009195 |
| us-gaap | IncreaseDecreaseInCustomerDeposits | Increase (Decrease) in Customer Deposits | USD | 32,000 | 2019-01-01 | 2019-09-30 | 2019 | Q3 | 10-Q | 2020-03-09 | 0001121781-20-000018 |
| us-gaap | IncreaseDecreaseInDeferredRevenue | Increase (Decrease) in Deferred Revenue | USD | 80,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | IncreaseDecreaseInDerivativeLiabilities | Increase (Decrease) in Derivative Liabilities | USD | 2.20M | 2021-01-01 | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-18 | 0001654954-21-009195 |
| us-gaap | IncreaseDecreaseInInsuranceSettlementsReceivable | Increase (Decrease) in Insurance Settlements Receivable | USD | -3.62M | 2011-01-01 | 2011-12-31 | 2011 | FY | 10-K | 2012-03-28 | 0001121781-12-000081 |
| us-gaap | IncreaseDecreaseInInventories | Increase (Decrease) in Inventories | USD | 62,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | IncreaseDecreaseInOperatingLeaseLiability | IncreaseDecreaseInOperatingLeaseLiability | USD | -22,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | IncreaseDecreaseInOtherCurrentAssets | Increase (Decrease) in Other Current Assets | USD | -95,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | IncreaseDecreaseInOtherNoncurrentAssets | Increase (Decrease) in Other Noncurrent Assets | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-30 | 0001477932-23-001899 |
| us-gaap | IncreaseDecreaseInOtherNoncurrentLiabilities | Increase (Decrease) in Other Noncurrent Liabilities | USD | 0 | 2016-01-01 | 2016-03-31 | 2016 | Q1 | 10-Q | 2016-05-19 | 0001121781-16-000472 |
| us-gaap | IncreaseDecreaseInOtherOperatingAssets | Increase (Decrease) in Other Operating Assets | USD | -1,000 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-04-20 | 0001654954-20-004236 |
| us-gaap | IncreaseDecreaseInOtherReceivables | Increase (Decrease) in Other Receivables | USD | 0 | 2021-01-01 | 2021-03-31 | 2021 | Q1 | 10-Q/A | 2021-08-18 | 0001654954-21-009188 |
| us-gaap | IncrementalCommonSharesAttributableToShareBasedPaymentArrangements | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements | shares | 47.29M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | InducedConversionOfConvertibleDebtExpense | Induced Conversion of Convertible Debt Expense | USD | 78,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | InterestAndDebtExpense | Interest and Debt Expense | USD | 1,000 | 2024-01-01 | 2024-06-30 | 2024 | Q2 | 10-Q | 2024-08-14 | 0001477932-24-004869 |
| us-gaap | InterestExpense | Interest Expense | USD | 287,000 | 2026-01-01 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-13 | 0001477932-26-004958 |
| us-gaap | InterestExpenseNonoperating | InterestExpenseNonoperating | USD | 442,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | InterestIncomeOperating | Interest Income, Operating | USD | 0 | 2025-01-01 | 2025-06-30 | 2025 | Q2 | 10-Q | 2025-08-14 | 0001477932-25-005887 |
| us-gaap | InterestIncomeOther | Interest Income, Other | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 |
| us-gaap | InterestPaid | Interest Paid, Including Capitalized Interest, Operating and Investing Activities | USD | 97,000 | 2023-01-01 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-13 | 0001477932-23-008286 |
| us-gaap | InterestPaidNet | Interest Paid, Excluding Capitalized Interest, Operating Activities | USD | 48,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | InterestPayableCurrent | Interest Payable, Current | USD | 488,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | InventoryFinishedGoods | Inventory, Finished Goods, Gross | USD | 11,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | InventoryFinishedGoodsNetOfReserves | Inventory, Finished Goods, Net of Reserves | USD | 818,000 | 2025-03-31 | 2025 | Q1 | 10-Q | 2025-05-15 | 0001477932-25-003835 | |
| us-gaap | InventoryLIFOReservePeriodCharge | Inventory, LIFO Reserve, Period Charge | USD | -73,000 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-04-07 | 0001654954-21-003915 |
| us-gaap | InventoryNet | Inventory, Net | USD | 511,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | InventoryRawMaterials | Inventory, Raw Materials, Gross | USD | 1.25M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | InventoryValuationReserves | Inventory Valuation Reserves | USD | 818,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | InventoryWorkInProcess | Inventory, Work in Process, Gross | USD | 69,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | InventoryWriteDown | Inventory Write-down | USD | -26,000 | 2015-01-01 | 2015-12-31 | 2015 | FY | 10-K | 2016-03-15 | 0001121781-16-000420 |
| us-gaap | InvestmentIncomeDividend | Investment Income, Dividend | USD | 0 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-05-08 | 0001654954-19-005469 |
| us-gaap | InvestmentIncomeInterestAndDividend | Investment Income, Interest and Dividend | USD | 1.38 | 2012-07-01 | 2012-07-30 | 2012 | Q3 | 10-Q | 2012-11-13 | 0001121781-12-000323 |
| us-gaap | InvestmentInterestRate | Investment Interest Rate | pure | 0.24 | 2020-05-27 | 2022 | Q2 | 10-Q | 2022-08-15 | 0001477932-22-006064 | |
| us-gaap | IssuanceOfStockAndWarrantsForServicesOrClaims | Issuance of Stock and Warrants for Services or Claims | USD | 3.62M | 2011-01-01 | 2011-12-31 | 2012 | FY | 10-K | 2013-03-27 | 0001121781-13-000037 |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDue | Lessee, Operating Lease, Liability, to be Paid | USD | 871,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive | Lessee, Operating Lease, Liability, to be Paid, after Year Five | USD | 114,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths | Lessee, Operating Lease, Liability, to be Paid, Year One | USD | 41,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFive | Lessee, Operating Lease, Liability, to be Paid, Year Five | USD | 190,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFour | Lessee, Operating Lease, Liability, to be Paid, Year Four | USD | 182,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearThree | Lessee, Operating Lease, Liability, to be Paid, Year Three | USD | 175,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearTwo | Lessee, Operating Lease, Liability, to be Paid, Year Two | USD | 169,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year | USD | 30,000 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-13 | 0001477932-25-008196 | |
| us-gaap | LesseeOperatingLeaseLiabilityUndiscountedExcessAmount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | USD | 197,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | Liabilities | Liabilities | USD | 7.51M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 1.38M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 6.93M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | LiabilitiesFairValueDisclosureRecurring | Liabilities, Fair Value Disclosure, Recurring (Deprecated 2018-01-31) | USD | 6.27M | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-21 | 0001121781-18-000024 | |
| us-gaap | LiabilitiesNoncurrent | Liabilities, Noncurrent | USD | 580,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | LiabilityForFuturePolicyBenefitRemeasurementGainLoss | LiabilityForFuturePolicyBenefitRemeasurementGainLoss | USD | 160,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | LineOfCreditFacilityAverageOutstandingAmount | Line of Credit Facility, Average Outstanding Amount | USD | 129,556 | 2024-07-01 | 2024-07-04 | 2025 | Q2 | 10-Q | 2025-08-14 | 0001477932-25-005887 |
| us-gaap | LinesOfCreditCurrent | Line of Credit, Current | USD | 619 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-30 | 0001477932-23-001899 | |
| us-gaap | LoansInsurancePolicy | Loans, Gross, Insurance Policy | USD | 92,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | LoansPayableCurrent | Loans Payable, Current | USD | 177,000 | 2014-03-31 | 2014 | Q1 | 10-Q | 2014-05-15 | 0001121781-14-000134 | |
| us-gaap | LongTermDebt | Long-term Debt | USD | 140,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | LongTermDebtCurrent | Long-term Debt, Current Maturities | USD | 0 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-28 | 0001477932-24-001549 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths | Long-Term Debt, Maturity, Year One | USD | 86,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree | Long-Term Debt, Maturity, Year Three | USD | 23,000 | 2025-03-31 | 2025 | Q1 | 10-Q | 2025-05-15 | 0001477932-25-003835 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo | Long-Term Debt, Maturity, Year Two | USD | 23,000 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear | Long-Term Debt, Maturity, Remainder of Fiscal Year | USD | 54,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | LongTermDebtNoncurrent | Long-term Debt, Excluding Current Maturities | USD | 0 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-30 | 0001477932-23-001899 | |
| us-gaap | LongTermNotesPayable | Notes Payable, Noncurrent | USD | 5,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | MinorityInterest | Stockholders' Equity Attributable to Noncontrolling Interest | USD | 0 | 2012-12-31 | 2012 | FY | 10-K | 2013-03-27 | 0001121781-13-000037 | |
| us-gaap | MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders | Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders | USD | 104,000 | 2012-01-01 | 2012-12-31 | 2013 | FY | 10-K | 2014-03-26 | 0001121781-14-000055 |
| us-gaap | NetCashProvidedByUsedInContinuingOperations | Net Cash Provided by (Used in) Continuing Operations | USD | -277,000 | 2017-01-01 | 2017-06-30 | 2017 | Q2 | 10-Q | 2017-08-18 | 0001654954-17-007742 |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | 1.33M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -1.28M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -1.82M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | NetIncomeLossAvailableToCommonStockholdersBasic | Net Income (Loss) Available to Common Stockholders, Basic | USD | -2.34M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | NonoperatingIncomeExpense | Nonoperating Income (Expense) | USD | -60,000 | 2025-01-01 | 2025-06-30 | 2025 | Q2 | 10-Q | 2025-08-14 | 0001477932-25-005887 |
| us-gaap | NotesAndLoansPayable | Notes and Loans Payable | USD | 27,000 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-30 | 0001477932-22-001704 | |
| us-gaap | NotesAndLoansPayableCurrent | Notes and Loans Payable, Current | USD | 0 | 2019-12-31 | 2019 | Q3 | 10-Q | 2020-03-09 | 0001121781-20-000018 | |
| us-gaap | NotesIssued1 | Notes Issued | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-30 | 0001477932-23-001899 |
| us-gaap | NotesPayable | Notes Payable | USD | 135,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | NotesPayableCurrent | Notes Payable, Current | USD | 130,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | NotesPayableRelatedPartiesClassifiedCurrent | Notes Payable, Related Parties, Current | USD | 0 | 2023-03-31 | 2023 | Q1 | 10-Q | 2023-05-15 | 0001477932-23-003493 | |
| us-gaap | NotesPayableRelatedPartiesCurrentAndNoncurrent | Notes Payable, Related Parties | USD | 0 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-30 | 0001477932-22-001704 | |
| us-gaap | NotesPayableRelatedPartiesNoncurrent | Notes Payable, Related Parties, Noncurrent | USD | 497,170 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0001477932-22-008459 | |
| us-gaap | OperatingExpenses | Operating Expenses | USD | 1.45M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -1.36M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | OperatingLeaseCost | Operating Lease, Cost | USD | 109,404 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-28 | 0001477932-24-001549 |
| us-gaap | OperatingLeaseExpense | Operating Lease, Expense | USD | 126,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | OperatingLeaseLiability | Operating Lease, Liability | USD | 674,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | OperatingLeaseLiabilityCurrent | Operating Lease, Liability, Current | USD | 99,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | OperatingLeaseLiabilityNoncurrent | Operating Lease, Liability, Noncurrent | USD | 575,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | OperatingLeasePayments | Operating Lease, Payments | USD | 78,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | OperatingLeaseRightOfUseAsset | Operating Lease, Right-of-Use Asset | USD | 616,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | OperatingLeaseRightOfUseAssetAmortizationExpense | Operating Lease, Right-of-Use Asset, Amortization Expense | USD | 69,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDue | Operating Leases, Future Minimum Payments Due | USD | 159,000 | 2019-12-31 | 2019 | FY | 10-K | 2020-04-20 | 0001654954-20-004236 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueCurrent | Operating Leases, Future Minimum Payments Due, Next Twelve Months | USD | 120,000 | 2019-12-31 | 2019 | FY | 10-K | 2020-04-20 | 0001654954-20-004236 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFourYears | Operating Leases, Future Minimum Payments, Due in Four Years | USD | 26,000 | 2018-09-30 | 2018 | Q3 | 10-Q | 2018-11-14 | 0001121781-18-000063 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInThreeYears | Operating Leases, Future Minimum Payments, Due in Three Years | USD | 30,000 | 2019-09-30 | 2019 | Q3 | 10-Q | 2020-03-09 | 0001121781-20-000018 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInTwoYears | Operating Leases, Future Minimum Payments, Due in Two Years | USD | 30,000 | 2019-12-31 | 2019 | FY | 10-K | 2020-04-20 | 0001654954-20-004236 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear | Operating Leases, Future Minimum Payments, Remainder of Fiscal Year | USD | 29,000 | 2019-09-30 | 2019 | Q3 | 10-Q | 2020-03-09 | 0001121781-20-000018 | |
| us-gaap | OperatingLossCarryforwards | Operating Loss Carryforwards | USD | 66.30M | 2025-12-31 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | OtherAccruedLiabilitiesCurrent | Other Accrued Liabilities, Current | USD | 8,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | OtherAccruedLiabilitiesCurrentAndNoncurrent | Other Accrued Liabilities | USD | 7,000 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 | |
| us-gaap | OtherAssetsCurrent | Other Assets, Current | USD | 109,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | OtherAssetsNoncurrent | Other Assets, Noncurrent | USD | 17,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | OtherCommitment | Other Commitment | USD | 2,000 | 2024-04-15 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | OtherCostAndExpenseOperating | Other Cost and Expense, Operating | USD | 27,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | OtherEmployeeRelatedLiabilitiesCurrent | Other Employee-related Liabilities, Current | USD | 671,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | OtherExpenses | Other Expenses | USD | 2,000 | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-16 | 0001477932-22-003472 |
| us-gaap | OtherIncome | Other Income | USD | 14,000 | 2026-01-01 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-13 | 0001477932-26-004958 |
| us-gaap | OtherLiabilitiesNoncurrent | Other Liabilities, Noncurrent | USD | 262,000 | 2015-03-31 | 2015 | Q1 | 10-Q | 2015-05-13 | 0001121781-15-000121 | |
| us-gaap | OtherNoncashExpense | Other Noncash Expense | USD | 20,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | OtherNoncashIncomeExpense | Other Noncash Income (Expense) | USD | -7,000 | 2025-01-01 | 2025-03-31 | 2025 | Q1 | 10-Q | 2025-05-15 | 0001477932-25-003835 |
| us-gaap | OtherNonoperatingIncome | Other Nonoperating Income | USD | 16,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | OtherNonoperatingIncomeExpense | Other Nonoperating Income (Expense) | USD | -462,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | OtherNotesPayable | Other Notes Payable | USD | 5,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | OtherOperatingIncomeExpenseNet | Other Operating Income (Expense), Net | USD | 4,000 | 2022-01-01 | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-15 | 0001477932-22-006064 |
| us-gaap | OtherPreferredStockDividendsAndAdjustments | Other Preferred Stock Dividends and Adjustments | USD | 2,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | OtherReceivablesNetCurrent | Other Receivables, Net, Current | USD | 100,000 | 2020-03-31 | 2020 | Q1 | 10-Q | 2020-07-07 | 0001654954-20-007405 | |
| us-gaap | PaymentsForFees | Payments for Other Fees | USD | 31,650 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-30 | 0001477932-22-001704 |
| us-gaap | PaymentsForRent | Payments for Rent | USD | 750,000 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-30 | 0001477932-22-001704 |
| us-gaap | PaymentsOfDebtIssuanceCosts | Payments of Debt Issuance Costs | USD | 80,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | PaymentsOfDebtRestructuringCosts | Payments of Debt Restructuring Costs | USD | 125,000 | 2022-09-03 | 2022-09-08 | 2022 | FY | 10-K | 2023-03-30 | 0001477932-23-001899 |
| us-gaap | PaymentsOfLoanCosts | Payments of Loan Costs | USD | 281,000 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-04-20 | 0001654954-20-004236 |
| us-gaap | PaymentsToAcquireLoansReceivable | Payments to Acquire Loans Receivable | USD | 4,000 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | PaymentsToAcquireProductiveAssets | Payments to Acquire Productive Assets | USD | 0 | 2016-01-01 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-22 | 0001654954-17-002258 |
| us-gaap | PaymentsToAcquirePropertyPlantAndEquipment | Payments to Acquire Property, Plant, and Equipment | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | PaymentsToFundLongtermLoansToRelatedParties | Payments to Fund Long-term Loans to Related Parties | USD | 92,399 | 2022-06-01 | 2022-06-22 | 2022 | Q3 | 10-Q | 2022-11-14 | 0001477932-22-008459 |
| us-gaap | PreferredStockConvertibleSharesIssuable | PreferredStockConvertibleSharesIssuable | shares | 45.55M | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 | |
| us-gaap | PreferredStockDividendsAndOtherAdjustments | Preferred Stock Dividends and Other Adjustments | USD | -2,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | PreferredStockDividendsIncomeStatementImpact | Preferred Stock Dividends, Income Statement Impact | USD | 500,000 | 2025-01-01 | 2025-03-31 | 2025 | Q1 | 10-Q | 2025-05-15 | 0001477932-25-003835 |
| us-gaap | PreferredStockDividendsShares | Preferred Stock Dividends, Shares | shares | 65,000 | 2022-08-29 | 2022-09-01 | 2022 | Q3 | 10-Q | 2022-11-14 | 0001477932-22-008459 |
| us-gaap | PreferredStockLiquidationPreference | Preferred Stock, Liquidation Preference Per Share | USD/shares | 1,248 | 2017-06-30 | 2017 | Q2 | 10-Q | 2017-08-18 | 0001654954-17-007742 | |
| us-gaap | PreferredStockLiquidationPreferenceValue | Preferred Stock, Liquidation Preference, Value | USD | 286,000 | 2019-12-31 | 2019 | FY | 10-K | 2020-04-20 | 0001654954-20-004236 | |
| us-gaap | PreferredStockParOrStatedValuePerShare | Preferred Stock, Par or Stated Value Per Share | USD/shares | 0.001 | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-15 | 0001477932-22-006064 | |
| us-gaap | PreferredStockSharesAuthorized | Preferred Stock, Shares Authorized | shares | 5.00M | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-15 | 0001477932-22-006064 | |
| us-gaap | PreferredStockSharesIssued | Preferred Stock, Shares Issued | shares | 0.3 | 2019-12-31 | 2019 | FY | 10-K | 2020-04-20 | 0001654954-20-004236 | |
| us-gaap | PreferredStockSharesOutstanding | Preferred Stock, Shares Outstanding | shares | 0.3 | 2019-12-31 | 2019 | FY | 10-K | 2020-04-20 | 0001654954-20-004236 | |
| us-gaap | PreferredStockValue | Preferred Stock, Value, Issued | USD | 1.34M | 2013-06-30 | 2013 | Q2 | 10-Q | 2013-08-14 | 0001121781-13-000294 | |
| us-gaap | PremiumsPercentageAssumedToNet | SEC Schedule, 12-17, Insurance Companies, Reinsurance, Premium, Percentage Assumed to Net | pure | 0.5 | 2025-01-01 | 2025-12-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 |
| us-gaap | PrepaidExpenseAndOtherAssets | Prepaid Expense and Other Assets | USD | 356,000 | 2017-06-30 | 2017 | Q2 | 10-Q | 2017-08-18 | 0001654954-17-007742 | |
| us-gaap | PrepaidExpenseCurrentAndNoncurrent | Prepaid Expense | USD | 12,000 | 2016-09-30 | 2016 | Q3 | 10-Q | 2016-12-05 | 0001121781-16-000585 | |
| us-gaap | PrepaidInsurance | Prepaid Insurance | USD | 133,000 | 2016-09-30 | 2016 | Q3 | 10-Q | 2016-12-05 | 0001121781-16-000585 | |
| us-gaap | PriceRiskCashFlowHedgeLiabilityAtFairValue | Price Risk Cash Flow Hedge Liability, at Fair Value | USD | 50,000 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0001477932-22-008459 | |
| us-gaap | PrincipalAmountOutstandingOnLoansSecuritized | Principal Amount Outstanding on Loans Securitized or Asset-backed Financing Arrangement | USD | 625,444 | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-15 | 0001477932-22-006064 | |
| us-gaap | ProceedsFromDebtNetOfIssuanceCosts | Proceeds from Debt, Net of Issuance Costs | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-30 | 0001477932-23-001899 |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 0 | 2026-01-01 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-13 | 0001477932-26-004958 |
| us-gaap | ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan | Proceeds from Issuance of Common Stock, Dividend Reinvestment Plan | USD | 3.20M | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-30 | 0001477932-23-001899 |
| us-gaap | ProceedsFromIssuanceOfConvertiblePreferredStock | Proceeds from Issuance of Convertible Preferred Stock | USD | 0 | 2022-01-01 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0001477932-22-008459 |
| us-gaap | ProceedsFromIssuanceOfDebt | Proceeds from Issuance of Debt | USD | 526,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | ProceedsFromIssuanceOfLongTermDebt | Proceeds from Issuance of Long-term Debt | USD | 519,000 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-04-07 | 0001654954-21-003915 |
| us-gaap | ProceedsFromIssuanceOfPreferredStockAndPreferenceStock | Proceeds from Issuance of Preferred Stock and Preference Stock | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-30 | 0001477932-23-001899 |
| us-gaap | ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants | Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants | USD | 400,000 | 2024-01-01 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-14 | 0001477932-24-007162 |
| us-gaap | ProceedsFromIssuanceOfPrivatePlacement | Proceeds from Issuance of Private Placement | USD | 480,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | ProceedsFromIssuanceOfWarrants | Proceeds from Issuance of Warrants | USD | 400,000 | 2023-01-01 | 2023-12-31 | 2024 | FY | 10-K | 2025-03-31 | 0001477932-25-002200 |
| us-gaap | ProceedsFromIssuanceOrSaleOfEquity | Proceeds from Issuance or Sale of Equity | USD | 126,000 | 2018-01-01 | 2018-09-30 | 2018 | Q3 | 10-Q | 2018-11-14 | 0001121781-18-000063 |
| us-gaap | ProceedsFromNotesPayable | Proceeds from Notes Payable | USD | 526,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | ProceedsFromRelatedPartyDebt | Proceeds from Related Party Debt | USD | 160,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 |
| us-gaap | ProceedsFromRepurchaseOfEquity | Proceeds from (Repurchase of) Equity | USD | 217,000 | 2017-01-01 | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-22 | 0001121781-17-000030 |
| us-gaap | ProceedsFromSaleOfPropertyPlantAndEquipment | Proceeds from Sale of Property, Plant, and Equipment | USD | 56,000 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | ProceedsFromSaleOfTrustAssetsToPayExpenses | Proceeds from Sale of Trust Assets to Pay Expenses | USD | 3.20M | 2022-01-01 | 2022-12-31 | 2023 | Q3 | 10-Q | 2023-11-13 | 0001477932-23-008286 |
| us-gaap | ProceedsFromShortTermDebt | Proceeds from Short-term Debt | USD | -90,000 | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-16 | 0001477932-22-003472 |
| us-gaap | ProceedsFromStockOptionsExercised | Proceeds from Stock Options Exercised | USD | 1.83M | 2013-01-01 | 2013-06-30 | 2013 | Q2 | 10-Q | 2013-08-14 | 0001121781-13-000294 |
| us-gaap | ProceedsFromWarrantExercises | Proceeds from Warrant Exercises | USD | 980,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | ProductWarrantyAccrual | Standard and Extended Product Warranty Accrual | USD | 2,000 | 2019-12-31 | 2019 | FY | 10-K | 2020-04-20 | 0001654954-20-004236 | |
| us-gaap | ProfitLoss | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | USD | -1.10M | 2026-01-01 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-13 | 0001477932-26-004958 |
| us-gaap | ProFormaWeightedAverageSharesOutstandingDiluted | Pro Forma Weighted Average Shares Outstanding, Diluted | shares | 27.34M | 2022-01-01 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0001477932-22-008459 |
| us-gaap | PropertyPlantAndEquipmentDisposals | Property, Plant and Equipment, Disposals | USD | 647,000 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-04-07 | 0001654954-21-003915 |
| us-gaap | PropertyPlantAndEquipmentGross | Property, Plant and Equipment, Gross | USD | 1.59M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | PropertyPlantAndEquipmentNet | Property, Plant and Equipment, Net | USD | 9,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | ProvisionForDoubtfulAccounts | Accounts Receivable, Credit Loss Expense (Reversal) | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | RepaymentsOfDebt | Repayments of Debt | USD | 10,000 | 2024-07-01 | 2024-07-23 | 2024 | Q3 | 10-Q | 2024-11-14 | 0001477932-24-007162 |
| us-gaap | RepaymentsOfNotesPayable | Repayments of Notes Payable | USD | 571,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | RepaymentsOfRelatedPartyDebt | Repayments of Related Party Debt | USD | 2,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | RepurchaseAgreementsInterestExpenseAmount | Repurchase Agreements, Interest Expense Amount | USD | 29,776 | 2022-06-01 | 2022-06-22 | 2022 | Q3 | 10-Q | 2022-11-14 | 0001477932-22-008459 |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 282,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | RestructuringReserve | Restructuring Reserve | USD | 972,000 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-15 | 0001654954-21-012222 | |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -159.39M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | RevenueRemainingPerformanceObligation | Revenue, Remaining Performance Obligation, Amount | USD | 7,442 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-13 | 0001477932-23-008286 | |
| us-gaap | Revenues | Revenues | USD | 92,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | RevenuesFromExternalCustomers | Revenue from External Customers (Deprecated 2013-01-31) | USD | 653,000 | 2013-01-01 | 2013-12-31 | 2013 | FY | 10-K | 2014-03-26 | 0001121781-14-000055 |
| us-gaap | RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | USD | 642,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | SaleOfStockPricePerShare | Sale of Stock, Price Per Share | USD/shares | 0.29 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | SalesRevenueNet | Revenue, Net (Deprecated 2018-01-31) | USD | 4,000 | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-21 | 0001121781-18-000024 |
| us-gaap | SellingAndMarketingExpense | Selling and Marketing Expense | USD | 68,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | ServicingLiabilityAtFairValueOtherChangesInFairValue | Servicing Liability at Fair Value, Other Changes in Fair Value | USD | -8,000 | 2024-01-01 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-14 | 0001477932-24-007162 |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 101,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage | Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage | pure | 0.25 | 2021-01-01 | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-18 | 0001654954-21-009195 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price | USD/shares | 0.25 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | pure | 0 | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | pure | 1.934 | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | pure | 0.038 | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised | shares | 4.83M | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations | shares | 900,000 | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted | shares | 5.18M | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Other | shares | 4.83M | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number | shares | 32.39M | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-14 | 0001477932-24-007162 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant | Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares | 26,616 | 2015-12-31 | 2015 | FY | 10-K | 2016-03-15 | 0001121781-16-000420 | |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | USD | 91,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares | 2.65M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | USD/shares | 0.31 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | USD | 0 | 2014-01-01 | 2014-09-30 | 2014 | Q3 | 10-Q | 2014-11-12 | 0001121781-14-000322 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period | shares | 657,431 | 2025-01-01 | 2025-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period | shares | 0 | 2021-01-01 | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-18 | 0001654954-21-009195 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price | USD/shares | 0.26 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-28 | 0001477932-24-001549 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Intrinsic Value | USD/shares | 0 | 2014-01-01 | 2014-09-30 | 2014 | Q3 | 10-Q | 2014-11-12 | 0001121781-14-000322 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares | 24,205 | 2025-01-01 | 2025-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | shares | 625,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value | USD/shares | 0 | 2014-01-01 | 2014-09-30 | 2014 | Q3 | 10-Q | 2014-11-12 | 0001121781-14-000322 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares | 625,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | USD/shares | 0.14 | 2025-01-01 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-13 | 0001477932-25-008196 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares | shares | 1 | 2017-12-31 | 2017 | FY | 10-K/A | 2018-04-20 | 0001654954-18-004170 | |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares | shares | 7 | 2017-01-01 | 2017-12-31 | 2017 | FY | 10-K/A | 2018-04-20 | 0001654954-18-004170 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value | USD/shares | 48,613 | 2017-01-01 | 2017-12-31 | 2017 | FY | 10-K/A | 2018-04-20 | 0001654954-18-004170 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price | USD/shares | 0 | 2017-12-31 | 2017 | FY | 10-K/A | 2018-04-20 | 0001654954-18-004170 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | USD | 135,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares | 3.45M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | USD/shares | 0.39 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value | USD | 56.83M | 2015-03-31 | 2015 | Q1 | 10-Q | 2015-05-13 | 0001121781-15-000121 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | USD | 56.83M | 2015-03-31 | 2015 | Q1 | 10-Q | 2015-05-13 | 0001121781-15-000121 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | shares | 117 | 2017-12-31 | 2017 | FY | 10-K/A | 2018-04-20 | 0001654954-18-004170 | |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | shares | 0 | 2017-01-01 | 2017-12-31 | 2017 | FY | 10-K/A | 2018-04-20 | 0001654954-18-004170 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value | USD/shares | 0 | 2017-01-01 | 2017-12-31 | 2017 | FY | 10-K/A | 2018-04-20 | 0001654954-18-004170 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum | Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum | pure | 0.1 | 2022-01-01 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0001477932-22-008459 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | shares | 15.32M | 2022-01-01 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0001477932-22-008459 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | USD/shares | 0.15 | 2023-01-01 | 2023-12-31 | 2024 | FY | 10-K | 2025-03-31 | 0001477932-25-002200 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price | USD/shares | 0.45 | 2025-01-01 | 2025-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | USD/shares | 0.21 | 2025-01-01 | 2025-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | USD/shares | 0.29 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 | Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price | USD/shares | 0.28 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | SharePrice | Share Price | USD/shares | 0.4 | 2025-06-30 | 2025 | Q2 | 10-Q | 2025-08-14 | 0001477932-25-005887 | |
| us-gaap | SharesIssued | Shares, Issued | shares | 116,364 | 2025-03-31 | 2025 | Q1 | 10-Q | 2025-05-15 | 0001477932-25-003835 | |
| us-gaap | SharesIssuedPricePerShare | Shares Issued, Price Per Share | USD/shares | 0.04 | 2019-12-17 | 2025 | Q3 | 10-Q | 2025-11-13 | 0001477932-25-008196 | |
| us-gaap | SharesOutstanding | Shares, Outstanding | shares | 86.15M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 | |
| us-gaap | ShortTermBankLoansAndNotesPayable | Short-term Bank Loans and Notes Payable | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 | |
| us-gaap | ShortTermBorrowings | Short-term Debt | USD | 646,000 | 2019-12-31 | 2019 | FY | 10-K | 2020-04-20 | 0001654954-20-004236 | |
| us-gaap | ShorttermDebtFairValue | Short-term Debt, Fair Value | USD | 431,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | ShortTermDebtInterestRateIncrease | Short-term Debt, Interest Rate Increase | pure | 0.033 | 2022-01-01 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0001477932-22-008459 |
| us-gaap | ShortTermNonBankLoansAndNotesPayable | Short-term Non-bank Loans and Notes Payable | USD | 47,162 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 | |
| us-gaap | StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants | Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants | USD | 15.94M | 2012-07-01 | 2012-07-30 | 2012 | Q3 | 10-Q | 2012-11-13 | 0001121781-12-000323 |
| us-gaap | StockGrantedDuringPeriodValueSharebasedCompensationForfeited | Shares Granted, Value, Share-based Payment Arrangement, Forfeited | USD | 178,000 | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | -6.14M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | StockholdersEquityBeforeTreasuryStock | Stockholders' Equity before Treasury Stock | USD | -132,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 | |
| us-gaap | StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | USD | -5.20M | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 | |
| us-gaap | StockIssued1 | Stock Issued | USD | 104,000 | 2024-01-01 | 2024-06-30 | 2024 | Q2 | 10-Q | 2024-08-14 | 0001477932-24-004869 |
| us-gaap | StockIssuedDuringPeriodSharesConversionOfUnits | Stock Issued During Period, Shares, Conversion of Units | shares | 6.75M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 |
| us-gaap | StockIssuedDuringPeriodSharesIssuedForServices | Stock Issued During Period, Shares, Issued for Services | shares | 98,000 | 2021-01-01 | 2021-12-31 | 2022 | FY | 10-K | 2023-03-30 | 0001477932-23-001899 |
| us-gaap | StockIssuedDuringPeriodSharesNewIssues | Stock Issued During Period, Shares, New Issues | shares | 813,916 | 2025-01-01 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-13 | 0001477932-25-008196 |
| us-gaap | StockIssuedDuringPeriodSharesOther | Stock Issued During Period, Shares, Other | shares | 813,916 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 |
| us-gaap | StockIssuedDuringPeriodSharesShareBasedCompensation | Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture | shares | 200,000 | 2014-01-01 | 2014-12-31 | 2014 | FY | 10-K | 2015-03-25 | 0001121781-15-000054 |
| us-gaap | StockIssuedDuringPeriodSharesShareBasedCompensationForfeited | Shares Issued, Shares, Share-based Payment Arrangement, Forfeited | shares | 3,262 | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-16 | 0001477932-22-003472 |
| us-gaap | StockIssuedDuringPeriodSharesStockOptionsExercised | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares | 0 | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-15 | 0001654954-21-012222 |
| us-gaap | StockIssuedDuringPeriodValueConversionOfConvertibleSecurities | Stock Issued During Period, Value, Conversion of Convertible Securities | USD | 203,000 | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 |
| us-gaap | StockIssuedDuringPeriodValueConversionOfUnits | Stock Issued During Period, Value, Conversion of Units | USD | 2.56M | 2021-01-01 | 2021-03-31 | 2021 | Q1 | 10-Q | 2021-05-21 | 0001654954-21-006101 |
| us-gaap | StockIssuedDuringPeriodValueIssuedForCash | Development Stage Entities, Stock Issued, Value, Issued for Cash (Deprecated 2015-01-31) | USD | 162,000 | 2012-01-01 | 2012-12-31 | 2012 | FY | 10-K | 2013-03-27 | 0001121781-13-000037 |
| us-gaap | StockIssuedDuringPeriodValueIssuedForServices | Stock Issued During Period, Value, Issued for Services | USD | 592,000 | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-16 | 0001477932-22-003472 |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 205,000 | 2025-01-01 | 2025-03-31 | 2026 | Q1 | 10-Q | 2026-05-15 | 0001477932-26-003195 |
| us-gaap | StockIssuedDuringPeriodValueOther | Stock Issued During Period, Value, Other | USD | 0 | 2022-01-01 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0001477932-22-008459 |
| us-gaap | StockIssuedDuringPeriodValueShareBasedCompensation | Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture | USD | 60,000 | 2024-01-01 | 2024-06-30 | 2024 | Q2 | 10-Q | 2024-08-14 | 0001477932-24-004869 |
| us-gaap | StockIssuedDuringPeriodValueStockDividend | Stock Issued During Period, Value, Stock Dividend | USD | 14,000 | 2021-01-01 | 2021-03-31 | 2021 | Q1 | 10-Q/A | 2021-08-18 | 0001654954-21-009188 |
| us-gaap | StockOptionExercisePriceIncrease | Stock Option, Exercise Price, Increase | USD/shares | 0.65 | 2022-08-29 | 2022-09-01 | 2023 | FY | 10-K | 2024-03-28 | 0001477932-24-001549 |
| us-gaap | StockOptionPlanExpense | Stock or Unit Option Plan Expense | USD | 93,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | StockRepurchasedDuringPeriodShares | Stock Repurchased During Period, Shares | shares | 300,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 |
| us-gaap | TemporaryEquityCarryingAmountAttributableToParent | Temporary Equity, Carrying Amount, Attributable to Parent | USD | 50,000 | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-18 | 0001654954-21-009195 | |
| us-gaap | TreasuryStockCommonValue | Treasury Stock, Common, Value | USD | 132,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 | |
| us-gaap | TreasuryStockValue | Treasury Stock, Value | USD | 132,000 | 2025-03-31 | 2025 | Q1 | 10-Q | 2025-05-15 | 0001477932-25-003835 | |
| us-gaap | UnamortizedDebtIssuanceExpense | Unamortized Debt Issuance Expense | USD | 48,000 | 2015-12-31 | 2015 | FY | 10-K | 2016-03-15 | 0001121781-16-000420 | |
| us-gaap | UnrealizedGainLossOnDerivatives | Unrealized Gain (Loss) on Derivatives | USD | -91,000 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-30 | 0001477932-22-001704 |
| us-gaap | UnrecognizedTaxBenefits | Unrecognized Tax Benefits | USD | 312,693 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-15 | 0001654954-21-012222 | |
| us-gaap | UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward | Unrecognized Tax Benefits Resulting in Net Operating Loss Carryforward (Deprecated 2014-01-31) | USD | 61.80M | 2012-12-31 | 2012 | FY | 10-K | 2013-03-27 | 0001121781-13-000037 | |
| us-gaap | WarrantExercisePriceDecrease | Warrant, Exercise Price, Decrease | USD/shares | 0.15 | 2022-08-29 | 2022-09-02 | 2025 | Q3 | 10-Q | 2025-11-13 | 0001477932-25-008196 |
| us-gaap | WarrantExercisePriceIncrease | Warrant, Exercise Price, Increase | USD/shares | 1.5 | 2021-05-01 | 2021-05-17 | 2025 | FY | 10-K | 2026-03-31 | 0001477932-26-001723 |
| us-gaap | WarrantsAndRightsOutstanding | Warrants and Rights Outstanding | USD | 873,000 | 2013-06-30 | 2013 | Q2 | 10-Q | 2013-08-14 | 0001121781-13-000294 | |
| us-gaap | WarrantsNotSettleableInCashFairValueDisclosure | Warrants Not Settleable in Cash, Fair Value Disclosure | USD | 0 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-30 | 0001477932-22-001704 | |
| us-gaap | WeightedAverageLimitedPartnershipUnitsOutstandingDiluted | Weighted Average Limited Partnership Units Outstanding, Diluted | shares | 13.38M | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-30 | 0001477932-22-001704 |
| us-gaap | WeightedAverageNumberBasicSharesOutstandingAdjustmentProForma | Weighted Average Number Basic Shares Outstanding Adjustment, Pro Forma | shares | 68.29M | 2025-01-01 | 2025-03-31 | 2025 | Q1 | 10-Q | 2025-05-15 | 0001477932-25-003835 |
| us-gaap | WeightedAverageNumberDilutedSharesOutstandingAdjustment | Weighted Average Number Diluted Shares Outstanding Adjustment | shares | 68.29M | 2025-01-01 | 2025-03-31 | 2025 | Q1 | 10-Q | 2025-05-15 | 0001477932-25-003835 |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 94.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | WeightedAverageNumberOfShareOutstandingBasicAndDiluted | Weighted Average Number of Shares Outstanding, Basic and Diluted | shares | 946 | 2017-01-01 | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-22 | 0001121781-17-000030 |
| us-gaap | WeightedAverageNumberOfSharesIssuedBasic | Weighted Average Number of Shares Issued, Basic | shares | 94.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 94.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001477932-26-007012 |